STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 166552

TO: Dwayne C Jones Location: REM/3B87/3C70 Art Unit: 1614 Monday, May 15, 2006 Case Serial Number: 10/735561	From: Alex Waclawiw Location: Biotech-Chem Library Rem 1A71 Phone: 272-2534 Alexandra.waclawiw@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Wayne C Jaeger Examiner #: 71994 Date: 21APR06

Art Unit: 1614 Phone Number: 2-0577 Serial Number: 10/735,564

Location (Bldg/Room#): 3D17 (Mailbox #): 3670 Results Format Preferred (circle): PAPER DISK

****

KEM

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: please see attached sheet

Inventors (please provide full names):

Earliest Priority Date: 07 Dec 13DEC 2002

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search claims 1, 2.

and where R, R1, R2 [illegible]

****

STAFF USE ONLY

Searcher: Point of Contact: Alexandra Waclawiw Technical Info. Specialist

Searcher Phone #: [illegible] Tel: 308-4691

Searcher Location:

Date Searcher Picked Up: 5/5

Date Completed: 5/8

Searcher Prep & Review Time: 1.2

Online Time: 5.6

Type of Search

___ NA Sequence (#)

___ AA Sequence (#)

___ Structure (#)

___ Bibliographic

___ Litigation

___ Fulltext

___ Other

Vendors and cost where applicable

✓ STN ___ Dialog

___ Questel/Orbit ___ Lexis/Nexis

___ Westlaw ___ WWW/Internet

___ In-house sequence systems

___ Commercial ___ Oligomer ___ Score/Length

___ Interference ___ SPDI ___ Encode/Transl

___ Other (specify)

37

```
$
=> d his ful

     (FILE 'CAPLUS' ENTERED AT 12:12:47 ON 15 MAY 2006)
               DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 12:12:53 ON 15 MAY 2006
               ACT JONES/A
               ---------
L1              STR
L2          270 SEA SSS FUL L1
               ---------
               ACT JONESSUB/A
               ---------
L3              STR
L4   (      270)SEA SSS FUL L3
L5   (       48)SEA ABB=ON  PLU=ON  L4 AND C10H19NO2
L6   (       42)SEA ABB=ON  PLU=ON  L5 AND C5/ES
L7   (       36)SEA ABB=ON  PLU=ON  L6 AND DIMETHYL
L8           10 SEA ABB=ON  PLU=ON  L7 AND 3 4 DIMETHYL
               ---------
L9          260 SEA ABB=ON  PLU=ON  L2 NOT L8


     FILE 'CAPLUS' ENTERED AT 12:16:52 ON 15 MAY 2006
L10          47 SEA ABB=ON  PLU=ON  L2
L11          29 SEA ABB=ON  PLU=ON  L8
L12          29 SEA ABB=ON  PLU=ON  L10 AND L11
L13           1 SEA ABB=ON  PLU=ON  L12 AND (SLEEP DISOR?)/TI
L14          28 SEA ABB=ON  PLU=ON  L12 NOT L13
L15          18 SEA ABB=ON  PLU=ON  L10 NOT L12

=> d que sta l2

L1              STR
```





Ak @25

```
VAR G1=25/H
VAR G2=3/8
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  25
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  SAT  AT  25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
```

L2 270 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 1314 ITERATIONS 270 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l8

L3 STR

G2 1





Ak @25

VAR G1=25/H
VAR G2=3/8
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 25
DEFAULT MLEVEL IS ATOM
GGCAT IS LOC SAT AT 25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L4 (270)SEA FILE=REGISTRY SSS FUL L3
L5 (48)SEA FILE=REGISTRY ABB=ON PLU=ON L4 AND C10H19NO2
L6 (42)SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND C5/ES
L7 (36)SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND DIMETHYL
L8 10 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND 3 4 DIMETHYL

=> fil reg
FILE 'REGISTRY' ENTERED AT 12:27:45 ON 15 MAY 2006

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6
DICTIONARY FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> d que sta l2
L1               STR
```




```
VAR G1=25/H
VAR G2=3/8
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  25
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  SAT  AT  25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L2          270 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED    1314 ITERATIONS                 270 ANSWERS
SEARCH TIME: 00.00.01
```

↳ claim 1

```
=> d que sta l8
L3                STR
```




```
VAR G1=25/H
VAR G2=3/8
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  25
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  SAT  AT  25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L4   (       270)SEA FILE=REGISTRY SSS FUL L3
L5   (        48)SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND C10H19NO2
L6   (        42)SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND C5/ES
L7   (        36)SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND DIMETHYL
L8            10 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND 3 4 DIMETHYL
```

↳ claim 2

```
=> fil caplus
FILE 'CAPLUS' ENTERED AT 12:27:52 ON 15 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 May 2006  VOL 144 ISS 21
FILE LAST UPDATED: 14 May 2006  (20060514/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE
```

```
=> d que nos l13 ;d que nos l14; d que nos l15
L1              STR
L2          270 SEA FILE=REGISTRY SSS FUL L1
L3              STR
L4   (      270)SEA FILE=REGISTRY SSS FUL L3
L5   (       48)SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND C10H19NO2
L6   (       42)SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND C5/ES
L7   (       36)SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND DIMETHYL
L8           10 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND 3 4 DIMETHYL
L10          47 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L11          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8
L12          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 AND L11
L13           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 AND (SLEEP DISOR?)/TI


L1              STR
L2          270 SEA FILE=REGISTRY SSS FUL L1
L3              STR
L4   (      270)SEA FILE=REGISTRY SSS FUL L3
L5   (       48)SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND C10H19NO2
L6   (       42)SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND C5/ES
L7   (       36)SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND DIMETHYL
L8           10 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND 3 4 DIMETHYL
L10          47 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L11          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8
L12          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 AND L11
L13           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 AND (SLEEP DISOR?)/TI
L14          28 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 NOT L13


L1              STR
L2          270 SEA FILE=REGISTRY SSS FUL L1
L3              STR
L4   (      270)SEA FILE=REGISTRY SSS FUL L3
L5   (       48)SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND C10H19NO2
L6   (       42)SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND C5/ES
L7   (       36)SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND DIMETHYL
L8           10 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND 3 4 DIMETHYL
L10          47 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L11          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8
L12          29 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 AND L11
L15          18 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 NOT L12
```

these all include claim 2

claim 1 but not structures of claim 2

```
=> d .ca l13 1; d .ca histr l14 1-28;d .ca hitstr l15 1-18

L13  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:10269  CAPLUS
DOCUMENT NUMBER:          136:79785
TITLE:                    Gabapentin analogs for sleep
                          disorders
INVENTOR(S):              Bryans, Justin Stephen; Meltzer, Leonard Theodore
PATENT ASSIGNEE(S):       Warner-Lambert Co., USA
SOURCE:                   PCT Int. Appl., 36 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000209	A2	20020103	WO 2001-US16343	20010518
WO 2002000209	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414008	AA	20020103	CA 2001-2414008	20010518
EP 1296671	A2	20030402	EP 2001-939192	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011913	A	20040106	BR 2001-11913	20010518
JP 2004501189	T2	20040115	JP 2002-504991	20010518
NZ 522480	A	20050624	NZ 2001-522480	20010518
ZA 2002009418	A	20050310	ZA 2002-9418	20021119
US 2003212133	A1	20031113	US 2002-297827	20021211
PRIORITY APPLN. INFO.:			US 2000-214171P P	20000626
			WO 2001-US16343 W	20010518

OTHER SOURCE(S): MARPAT 136:79785
ED Entered STN: 04 Jan 2002
GI



I



II

AB The invention provides a new use of compds. I [R = H, lower alkyl; R1-R8 = H, (un)branched C1-6 alkyl, Ph, benzyl, F, Cl, Br, OH, etc.] and II [R = H, lower alkyl; R9-R14 = H, (un)branched C1-6 alkyl, Ph, benzyl, F, Cl, Br, OH, etc.], or a pharmaceutically acceptable salt thereof. The compds. are useful in the treatment of insomnia and related disorders.

IC ICM A61K031-00
CC 1-11 (Pharmacology)
IT 60142-96-3D, Gabapentin, analogs **223425-82-9 223425-83-0**
223425-85-2 223425-89-6 223425-90-9
223425-91-0 223425-92-1 223425-93-2
223425-94-3 223425-95-4 223425-97-6
223425-98-7 223425-99-8 223426-00-4
223426-01-5 223426-02-6 223426-03-7
223426-04-8 223426-05-9 223426-07-1
223426-08-2 223426-09-3 223426-10-6
223426-11-7 223426-12-8 223426-13-9
223426-14-0 223426-16-2 223426-17-3
223426-18-4 223426-19-5 223426-20-8

223426-21-9 223426-22-0 223426-23-1
223426-24-2 223426-25-3 223426-26-4
223426-27-5 223426-28-6 223426-29-7
223426-30-0 223426-31-1 223426-32-2
223426-33-3 223426-34-4 223426-35-5
223426-36-6 223426-37-7 223426-38-8
223426-39-9 223426-40-2 223426-42-4
223426-43-5 223426-44-6 223426-45-7
223426-46-8 223426-47-9 223426-48-0
223426-49-1 223426-50-4 223426-51-5
223426-52-6 223426-54-8 223426-55-9
223426-56-0 223426-57-1 223426-58-2
223426-60-6 223426-61-7 223426-62-8
223426-63-9 223426-64-0 223426-65-1
223426-66-2 223426-67-3 223426-68-4
223426-70-8 223426-71-9 223426-72-0
223426-74-2 223426-76-4 223426-77-5
223426-79-7 223426-80-0 223426-81-1
223426-82-2 223426-83-3 223426-84-4
223426-85-5 223426-86-6 223426-87-7
223426-88-8 223426-89-9 223426-90-2
223426-91-3 223426-92-4 223426-93-5
223426-94-6 223426-95-7 223426-96-8
223426-97-9 223426-98-0 223426-99-1
223427-00-7 223427-01-8 223427-02-9
223427-03-0 223427-04-1 223427-05-2
223427-06-3 223427-07-4 223427-08-5
223427-09-6 223427-10-9 223427-11-0
223427-12-1 223427-13-2 223427-15-4
223427-16-5 223427-17-6 223427-18-7
223427-20-1 223427-22-3 223427-23-4
223427-25-6 223427-26-7 223427-28-9
223427-30-3 223427-31-4 223427-32-5
223427-33-6 223427-34-7 223427-35-8
223427-37-0 223427-38-1 223427-39-2
223427-40-5 223427-42-7 223427-43-8
223427-45-0 223427-46-1 223427-47-2
223427-48-3 223427-49-4 223427-50-7
223427-51-8 223427-53-0 223427-54-1
223427-55-2 223427-56-3 223427-57-4
223427-58-5 223427-60-9 223427-61-0
223427-62-1 223427-63-2 223427-64-3
223427-65-4 223427-66-5 223427-67-6
223427-68-7 223427-69-8 223427-70-1
223427-71-2 223427-72-3 223427-73-4
223427-74-5 223427-76-7 223427-77-8
223427-78-9 223427-79-0 223427-80-3
223427-81-4 223427-82-5 223427-83-6
223427-84-7 223427-86-9 223427-87-0
223427-88-1 223427-89-2 223427-90-5
223427-91-6 223427-92-7 223427-93-8
223427-94-9 223427-95-0 223427-97-2
223427-98-3 223427-99-4 223428-00-0
223428-01-1 223428-02-2 223428-03-3
223428-04-4 223428-05-5 223428-06-6
223428-07-7 223428-08-8 223428-09-9
223428-10-2 223428-12-4 223428-13-5
223428-14-6 223428-15-7 223428-16-8
223428-17-9 223428-18-0 223428-19-1
223428-20-4 223428-21-5 223428-22-6

223428-58-8 223445-09-8 223445-66-7
223445-69-0 223445-70-3 223445-71-4
223445-72-5 223445-73-6 223445-74-7
223445-75-8 223445-76-9 223445-77-0
223445-78-1 223445-79-2 223445-80-5
223445-81-6 223445-82-7 223445-83-8
223445-84-9 223445-85-0 223445-86-1
223445-87-2 313651-33-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin analogs for sleep disorders)

IT **342652-27-1 385800-31-7 385800-39-5**
385800-40-8 385800-41-9 385800-82-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin analogs for sleep disorders)

=> d .ca hitstr l14 1-28;d .ca hitstr l15 1-18

L14 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1170963 CAPLUS
DOCUMENT NUMBER: 143:440755
TITLE: Combinations comprising α-2-δ ligands and NMDA receptor antagonists
INVENTOR(S): Hizue, Masanori; Imai, Aki; Toide, Katsuo
PATENT ASSIGNEE(S): Pfizer Japan, Inc., Japan; Pfizer Inc.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102390	A2	20051103	WO 2005-IB988	20050411

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-564374P P 20040422
ED Entered STN: 03 Nov 2005
AB The invention relates to a synergistic combination of an α-2-δ ligand and an NMDA receptor antagonist (preferably an NR2B antagonist) or pharmaceutically-acceptable salts, esters or pharmaceutical compns. and their use in the treatment of pain, particularly neuropathic pain, and disorders of the central nervous system. Synthetic examples describe the preparation of α-2-δ ligands, e.g., (3R,4R,5R)-3-amino-4,5-

dimethylheptanoic acid, useful in the combinations of the invention. The combination of 3-methylgabapentin as α-2-δ ligand and (-)-(R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone as NR2B antagonist produced synergy in ability to relieve neuropathic pain.

IC ICM A61K045-06
ICS A61K031-195; A61P029-00

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

IT 125-71-3, Dextromethorphan 6740-88-1, Ketamine 19982-08-2, Memantine 23210-56-2, Ifenprodil 60142-96-3, Gabapentin 134234-12-1, Traxoprodil 148553-50-8, Pregabalin 196608-53-4 202914-18-9, CHF-3381
223445-75-8 227625-35-6 227626-51-9 313651-33-1
335458-65-6 473924-33-3 610300-07-7 610300-19-1 610300-20-4
686766-42-7 686766-43-8 686766-87-0 688007-58-1 868561-90-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising α-2-δ ligands and NMDA receptor antagonists)

IT **223445-75-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising α-2-δ ligands and NMDA receptor antagonists)

RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1170698 CAPLUS
DOCUMENT NUMBER: 143:446634
TITLE: Combinations comprising EP4-receptor antagonists and α2δ ligands for treating pain
INVENTOR(S): Audoly, Laurent Pascal
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 267 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102389	A2	20051103	WO 2005-IB935	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-563863P P 20040420

ED Entered STN: 03 Nov 2005

AB The present invention relates to a combination of an EP4-receptor antagonist (e.g. 4-[[[[5-fluoro-2-(4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]benzoic acid) and an α2δ ligand (e.g. pregabalin), and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain. Although neither the compds. nor the methods of preparation are claimed, many example prepns. (many of which are reproduced from previously published patents) are included. 4-[(1S)-1-[[[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl]amino]ethyl]benzoic acid and pregabalin were tested for effectiveness against carrageenan-induced mech. hyperalgesia and the combination was significantly more effective than either substance alone.

IC ICM A61K045-06
ICS A61K031-196; A61P025-02; A61P029-00

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 25, 27

IT 60142-96-3, Gabapentin 148553-50-8, Pregabalin **223445-75-8**, ((3S,4S)-1-Aminomethyl-3,4-dimethylcyclopentyl)acetic acid 227625-35-6, 3-[(1-Aminomethylcyclohexyl)methyl]-4H-[1,2,4]oxadiazol-5-one 227626-51-9, [[1-(1H-Tetrazol-5-ylmethyl)cycloheptyl]methyl]amine 313651-33-1, (3S,5R)-3-Aminomethyl-5-methyloctanoic acid 335458-65-6, [(1α,3α,5α)-3-Aminomethylbicyclo[3.2.0]hept-3-yl]acetic acid 415904-13-1, 4-(6-Chloro-2-ethyl-5-trifluoromethyl-1H-benzimidazol-1-yl)phenethyl [(4-methylphenyl)sulfonyl]carbamate 415906-01-3, 2-[4-[2-(1,1-Dimethylethyl)-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 415906-55-7, 2-[4-[6-Chloro-2-ethyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]ethyl [(5-methyl-2-pyridinyl)sulfonyl]carbamate 415906-57-9, 2-[5-[6-Chloro-2-ethyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-2-pyridinyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 415906-73-9, N-[[[2-[4-[5,7-Dimethyl-2-(methylamino)-3H-imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 415906-78-4, 2-[4-[5,7-Dimethyl-2-(methylamino)-3H-imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 415906-83-1, 2-[4-[6-Chloro-2-(4-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 415907-18-5, N-[[[2-[4-[2-Ethyl-5-(1-hydroxy-1-methylethyl)-1H-benzimidazol-1-yl]phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 415907-55-0, 6-Chloro-2-ethyl-1-[4-[2-[N-methyl[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]-1H-benzimidazole-5-carboxamide 416844-64-9, 5-Acetyl-2-ethyl-3-[4-[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]benzimidazole 473924-33-3, [(1R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid 610300-07-7, (3S,5R)-3-Amino-5-methyloctanoic acid 610300-19-1, (3S,5R)-3-Amino-5-methylheptanoic acid 610300-20-4, (3S,5R)-3-Amino-5-methylnonanoic acid 616877-19-1, 2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 616877-21-5, 2-[4-[4-(4-Fluorophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 616877-23-7, N-[[[2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl]amino]carbonyl]-4-

methylbenzenesulfonamide 616877-24-8, N-[[[2-[4-[4-(4-Ethoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 616877-26-0, N-[[[2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl]amino]carbonyl]-4-methoxybenzenesulfonamide 616877-31-7, N-[[[2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl]amino]carbonyl]-2-fluorobenzenesulfonamide 616877-32-8, N-[[[2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl]amino]carbonyl]-3,4-dimethoxybenzenesulfonamide 616877-33-9, N-[[[2-[4-(3,5-Dimethyl-4-phenyl-1H-pyrazol-1-yl)phenyl]ethyl]amino]carbonyl]-2,4-difluorobenzenesulfonamide 616877-35-1, 2,4-Difluoro-N-[[[2-[4-[5-methyl-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl]amino]carbonyl]benzenesulfonamide 616877-36-2, 2-Fluoro-N-[[[2-[4-[5-methyl-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl]amino]carbonyl]benzenesulfonamide 616892-63-8, 2-[4-(2-Amino-4,5-diphenyl-1H-imidazol-1-yl)phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 616892-65-0, 2-[4-(2-Ethyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl [(4-methylphenyl)sulfonyl]carbamate 616892-67-2, N-[[[2-[4-(2-Ethyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 616892-69-4, 2-Chloro-N-[[[2-[4-(2-ethyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl]amino]carbonyl]benzenesulfonamide 616892-73-0, 2-[4-(2-Butyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl [(2-chlorophenyl)sulfonyl]carbamate 616892-75-2, 2-[4-(2-Isobutyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl [(2-chlorophenyl)sulfonyl]carbamate 616892-77-4, 2-[4-(2-Isopropyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl [(2-chlorophenyl)sulfonyl]carbamate 616892-79-6, 4-Chloro-N-[[[2-[4-(2-ethyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl]amino]carbonyl]benzenesulfonamide 616892-81-0, 2-[4-(2-tert-Butyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl [(2-chlorophenyl)sulfonyl]carbamate 616892-82-1, 4-Chloro-N-[[[2-[4-(2-isopropyl-4-phenyl-1H-imidazol-1-yl)phenyl]ethyl]amino]carbonyl]benzenesulfonamide 688007-58-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; combinations comprising EP4-receptor antagonists and α2δ ligands for treating pain)

IT **223445-75-8**, ((3S,4S)-1-Aminomethyl-3,4-dimethylcyclopentyl)acetic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; combinations comprising EP4-receptor antagonists and α2δ ligands for treating pain)

RN 223445-75-8 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1075617 CAPLUS
DOCUMENT NUMBER: 143:367000
TITLE: Preparation of atypical antipsychotics for

combinations with α-2-δ ligands
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092318	A1	20051006	WO 2005-IB510	20050224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:			
GB 2004-5200	A	20040308
US 2004-560416P	P	20040407

ED Entered STN: 07 Oct 2005

AB The instant invention relates to a combination, particularly a synergistic combination, of an α-2-δ ligand and an atypical antipsychotic, and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly neuropathic pain. (3R,4R,5R)-3-amino-4,5-dimethylheptanoic acid, an atypical antipsychotic, was prepared via a series of reactions starting with (S)-3-[(E)-2-methylpent-2-enoyl]-4-phenyloxazolidin-2-one. Example α-2-δ ligands include gabapentin.

IC ICM A61K031-197
ICS A61K031-401; A61K031-41; A61K031-496; A61K031-551; A61K031-5513; A61K031-517; A61K031-554; A61P025-00

CC 23-16 (Aliphatic Compounds)
Section cross-reference(s): 1, 28, 63

IT 60142-96-3, Gabapentin 146939-27-7, Ziprasidone 148553-50-8, Pregabalin **223445-75-8** 227625-35-6 313651-33-1 335458-65-6 473924-33-3 610300-07-7 610300-19-1 610300-20-4 686766-87-0 688007-58-1 866108-70-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of atypical antipsychotics for combinations with α-2-δ ligands)

IT **223445-75-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of atypical antipsychotics for combinations with α-2-δ ligands)

RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:472159 CAPLUS
DOCUMENT NUMBER: 143:26627
TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines with phosphodiesterase-5 (PDE5) inhibiting activity
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin Neil; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005049616	A1	20050602	WO 2004-IB3747		20041112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
NL 1027568	A1	20050526	NL 2004-1027568		20041123
NL 1027568	C2	20051130			
US 2005245544	A1	20051103	US 2004-997191		20041124
PRIORITY APPLN. INFO.:			GB 2003-27319	A	20031124
			US 2004-535797P	P	20040112

OTHER SOURCE(S): MARPAT 143:26627
ED Entered STN: 03 Jun 2005
GI



I



II

AB Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YCO2R15, YR16; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH2OCH2, alkylene, cycloalkylene; R15 = H, (substituted) alkyl; R16 = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared Thus, title compound (II) (preparation given) inhibited PDE-5 with IC50 = 0.075 nM.

IC ICM C07D487-04
ICS A61K031-505; A61P009-08

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 50-78-2, Aspirin 52-01-7, Spironolactone 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 77-36-1, Chlorthalidone 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 2609-46-3, Amiloride 3930-20-9, Sotalol 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 26839-75-8, Timolol 29094-61-9, Glipizide 29122-68-7, Atenolol 51384-51-1, Metoprolol 56211-40-6, Torsemide 60142-96-3, Gabapentin 72956-09-3, Carvedilol 74191-85-8, Doxazosin 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 81093-37-0, Pravastatin 85441-61-8, Quinapril 87333-19-5, Ramipril 88150-42-9, Amlodipine 93479-97-1, Glimepiride 107724-20-9, Eplerenone 111025-46-8, Pioglitazone 114798-26-4, Losartan 122320-73-4, Rosiglitazone 133040-01-4, Eprosartan 134523-00-5, Atorvastatin 137862-53-4, Valsartan 138402-11-6, Irbesartan 139481-59-7, Candesartan 144701-48-4, Telmisartan 148553-50-8, Pregabalin 209789-08-2, CI1027 **223445-75-8** 227625-35-6 227626-51-9 287714-41-4, Rosuvastatin 313651-33-1 335458-65-6 473924-33-3 610300-07-7 610300-19-1 610300-20-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

IT **223445-75-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

RN 223445-75-8 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:259678 CAPLUS
DOCUMENT NUMBER: 142:341889
TITLE: Pharmaceuticals containing combinations of an acetylcholine esterase inhibitor and α-2-δ receptor ligands
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065176	A1	20050324	US 2004-936416	20040908
WO 2005027975	A1	20050331	WO 2004-IB2981	20040908

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-22140 A 20030922
ED Entered STN: 25 Mar 2005
AB The instant invention relates to a combination of α-2-δ ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred α-2-δ ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept), tacrine (Cognex), rivastigmine (Exelon), physostigmine (Synapton), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil. Thus pessary compns. contained the above ingredient 250, anhydrous dextrose 380, potato starch 363, and Mg stearate 7 mg. The preparation of some of the compds. is given.
IC ICM A61K031-4745
ICS A61K031-195; A61K031-41
INCL 514291000; 514300000; 514381000; 514561000; 514294000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 23
IT 52-68-6, Promem 57-47-6, Synapton 59-99-4, Prostigmin 321-64-2,

Tacrine 357-70-0, Galantamine 1684-40-8, Cognex 1953-04-4, Reminyl 60142-96-3, Gabapentin 62732-44-9, Ipidacrine 90043-86-0, Amiridin 98833-92-2, Stacofylline 101246-66-6, Phenserine 101246-68-8, Eptastigmine 102518-79-6, Huperzine A 118909-22-1, Mentane 120011-70-3, Aricept 120014-06-4, Donepezil 123441-03-2, Exelon 124027-47-0, Velnacrine 132236-18-1, Zifrosilone 142852-50-4, Zanapezil 142852-51-5, TAK 147 145209-30-9, Tolserine 145209-50-3, Thiatolserine 145508-78-7, Icopezil 147606-23-3, CHF 2060 148261-35-2 148553-50-8, Pregabalin 149028-28-4, CI 1002 154619-76-8, MF 247 209394-46-7, TV 3326 **223445-75-8**, (3S,4S)-(1-Aminomethyl-3,4-dimethylcyclopentyl)acetic acid 227625-35-6, 3-(1-Aminomethylcyclohexylmethyl)-4H-[1,2,4]-oxadiazol-5-one 227626-51-9, C-[1-(1H-Tetrazol-5-ylmethyl)-cycloheptyl]methylamine 252264-92-9, T 82 263175-47-9, Huperzine X 273930-29-3, SPH 1286 290308-82-6, ER 127528 335458-65-6, (1α,3α,5α)-(3-Aminomethylbicyclo[3.2.0]hept-3-yl)acetic acid 402842-81-3, MF 8615 444667-97-4, RS 1259 473924-33-3 848347-50-2 848347-51-3 848442-09-1, E 2030 848442-10-4, MF 268 bitartrate hydrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing combinations of acetylcholine esterase inhibitor and α-2-δ receptor ligands)

IT **223445-75-8**, (3S,4S)-(1-Aminomethyl-3,4-dimethylcyclopentyl)acetic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing combinations of acetylcholine esterase inhibitor and α-2-δ receptor ligands)

RN 223445-75-8 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:238701 CAPLUS

DOCUMENT NUMBER: 142:316826

TITLE: A preparation of combinations comprising alpha-2-delta ligands and dual serotonin-noradrenaline reuptake inhibitors, useful for treatment of pain

INVENTOR(S): Dooley, David James; Field, Mark John; Williams, Richard Griffith

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005059715	A1	20050317	US 2004-935824	20040908

AU 2004271800 A1 20050324 AU 2004-271800 20040906
CA 2537402 AA 20050324 CA 2004-2537402 20040906
WO 2005025675 A1 20050324 WO 2004-IB2943 20040906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2003-502556P P 20030912
WO 2004-IB2943 W 20040906
ED Entered STN: 18 Mar 2005
GI



I

AB The invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline reuptake inhibitor (DSNRI) or one or both of a selective serotonin reuptake inhibitor (SSRI) and a selective noradrenaline reuptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly neuropathic pain (no biol. data). For instance, 3-amino-5-methyloctanoic acid hydrochloride (I•HCl) was prepared from (S)-citronellyl bromide in eight steps.

IC ICM A61K031-4245
ICS A61K031-195; A61K031-407; A61K031-137
INCL 514364000; 514412000; 514561000; 514650000
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT 60142-96-3, Gabapentin 148553-50-8, Pregabalin **223445-75-8**
227625-35-6 227626-51-9 313651-33-1 335458-65-6 473924-33-3
610300-07-7 610300-20-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alpha-2-delta ligand; pharmaceutical combinations comprising alpha-2-delta ligands and dual serotonin-noradrenaline reuptake inhibitors)
IT **223445-75-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alpha-2-delta ligand; pharmaceutical combinations comprising alpha-2-delta ligands and dual serotonin-noradrenaline reuptake inhibitors)
RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:162040 CAPLUS
DOCUMENT NUMBER: 142:233358
TITLE: Pharmaceutical composition using a nicotinic receptor partial agonist-α2δ ligand combination for the treatment of obesity or to facilitate or promote weight loss
INVENTOR(S): Coe, Jotham W.; O'Neill, Brian T.; Sands, Steven B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043406	A1	20050224	US 2004-870208	20040617
CA 2534271	AA	20050303	CA 2004-2534271	20040809
WO 2005018622	A1	20050303	WO 2004-IB2604	20040809
WO 2005018622	C1	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-497353P P 20030822
WO 2004-IB2604 W 20040809

ED Entered STN: 25 Feb 2005
AB Pharmaceutical compns. are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.
IC ICM A61K031-195
INCL 514561000
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 53492-40-3 60142-96-3, Gabapentin 68998-15-2 69718-72-5 148553-50-8, Pregabalin 196608-53-4 207391-08-0 207391-10-4

207391-12-6 207391-15-9 207391-18-2 207391-21-7 207391-24-0
207391-27-3 207391-28-4 207391-29-5 207391-34-2 207391-36-4
207391-37-5 207391-38-6 207391-40-0 207391-41-1 207391-42-2
207391-44-4 207391-63-7 207391-64-8 207391-65-9 207391-67-1
207391-74-0 **219135-91-8 219135-98-5** 219136-10-4
223445-75-8 227625-35-6 227626-49-5 227626-51-9
230615-75-5 248275-68-5 248275-79-8 248275-81-2 248275-95-8
248276-19-9 249296-44-4 287973-23-3 287973-26-6 287973-27-7
328055-76-1 328055-77-2 328055-78-3 328055-79-4 328055-80-7
328055-81-8 328055-83-0 328055-84-1 328055-85-2 328055-86-3
328055-87-4 328055-88-5 328055-89-6 328055-90-9 328055-92-1
328055-94-3 328055-95-4 328055-96-5 328055-97-6 328055-98-7
328055-99-8 328056-00-4 328056-01-5 328056-02-6 328056-03-7
328056-04-8 328056-05-9 328056-06-0 328056-07-1 328056-08-2
328056-09-3 328056-10-6 328056-11-7 328056-12-8 328056-13-9
328056-14-0 328056-15-1 328056-16-2 328056-17-3 328056-18-4
328056-19-5 328056-20-8 328056-21-9 328056-22-0 328056-23-1
328056-24-2 328056-25-3 328056-26-4 328056-27-5 328056-28-6
328056-29-7 328056-30-0 328056-66-2 335458-65-6 335458-69-0
357424-19-2 357424-20-5 415682-84-7 473924-33-3 610300-06-6
610300-07-7 610300-11-3 610300-12-4 610300-17-9 610300-18-0
610300-19-1 610300-20-4 610300-21-5 610300-22-6 610300-23-7
610300-24-8 610300-25-9 610300-26-0 610300-27-1 610300-28-2
610300-29-3 610300-30-6 610300-31-7 610300-32-8 610300-33-9
610300-34-0 641635-01-0 658683-13-7 658683-30-8 658683-32-0
658683-33-1 658683-34-2 658683-35-3 663623-18-5 663623-19-6
663623-20-9 663623-21-0 663623-22-1 663623-23-2 663623-24-3
663623-25-4 663623-26-5 663623-27-6 663623-28-7 663623-29-8
663623-31-2 663623-35-6 663623-36-7 663623-37-8 663623-38-9
663623-39-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic receptor partial agonist-α2δ ligand combination for treatment of obesity or to facilitate or promote weight loss)

IT **219135-91-8 219135-98-5 223445-75-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic receptor partial agonist-α2δ ligand combination for treatment of obesity or to facilitate or promote weight loss)

RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:162035 CAPLUS
DOCUMENT NUMBER: 142:233377
TITLE: Pharmaceutical composition and method using a combination of an opioid receptor antagonist and an α2δ ligand for the prevention and treatment of addiction in a mammal
INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043345	A1	20050224	US 2004-870821	20040617
CA 2535814	AA	20050303	CA 2004-2535814	20040809
WO 2005018670	A1	20050303	WO 2004-IB2602	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-497372P P 20030822
WO 2004-IB2602 W 20040809

ED Entered STN: 25 Feb 2005

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IC ICM A61K031-4745
ICS A61K031-407; A61K031-18

INCL 514300000; 514306000; 514602000; 514412000

CC 1-12 (Pharmacology)
Section cross-reference(s): 4, 63

IT 53492-40-3 60142-96-3 68998-15-2 148553-50-8 196608-53-4
219135-91-8 **219135-98-5** 219136-10-4
223445-75-8 227625-35-6 227626-49-5 227626-51-9
335458-65-6 335458-69-0 415682-84-7 473924-33-3 610300-06-6
610300-07-7 610300-11-3 610300-12-4 610300-17-9 610300-18-0
610300-19-1 610300-20-4 610300-21-5 610300-22-6 610300-23-7
610300-24-8 610300-25-9 610300-26-0 610300-27-1 610300-28-2
610300-29-3 610300-30-6 610300-31-7 610300-32-8 610300-33-9
610300-34-0 641635-01-0 658683-13-7 658683-30-8 658683-32-0
658683-33-1 658683-34-2 658683-35-3 663623-18-5 663623-19-6
663623-20-9 663623-21-0 663623-22-1 663623-23-2 663623-24-3
663623-25-4 663623-26-5 663623-27-6 663623-28-7 663623-29-8
663623-31-2 663623-35-6 663623-36-7 663623-37-8 663623-38-9
663623-39-0 774240-03-8 774240-05-0 774240-35-6 774240-43-6
774240-48-1 774240-49-2 774241-06-4 774241-07-5 774241-45-1
774241-53-1 774241-58-6 774241-59-7 778582-19-7 778582-23-3
778582-27-7 778582-32-4 778582-34-6 778582-60-8 845621-26-3
845621-27-4 845621-28-5 845621-29-6 845621-30-9 845621-31-0
845621-32-1 845621-33-2 845621-34-3 845621-35-4 845621-36-5
845621-37-6 845621-38-7 845621-39-8 845621-40-1 845621-41-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opioid receptor antagonist-α2δ ligand combination for prevention and treatment of addiction)

IT **219135-91-8 219135-98-5 223445-75-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opioid receptor antagonist-α2δ ligand combination for prevention and treatment of addiction)

RN 219135-91-8 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:160850 CAPLUS
DOCUMENT NUMBER: 142:233374
TITLE: Pharmaceutical composition using a combination of a nicotinic receptor partial agonist and an α2δ ligand for the prevention and treatment of addiction in a mammal
INVENTOR(S): Coe, Jotham W.; Sands, Steven B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043407	A1	20050224	US 2004-879616	20040629
CA 2535811	AA	20050303	CA 2004-2535811	20040809
WO 2005018621	A1	20050303	WO 2004-IB2603	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-497350P P 20030822
WO 2004-IB2603 W 20040809

ED Entered STN: 25 Feb 2005
AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine

dependence or addiction, alc. dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IC ICM A61K031-195
INCL 514561000
CC 1-12 (Pharmacology)
Section cross-reference(s): 4, 63

IT 53492-40-3 60142-96-3 68998-15-2 69718-72-5 148553-50-8
196608-53-4 207391-08-0 207391-10-4 207391-12-6 207391-15-9
207391-18-2 207391-21-7 207391-24-0 207391-27-3 207391-28-4
207391-29-5 207391-34-2 207391-36-4 207391-37-5 207391-38-6
207391-40-0 207391-41-1 207391-42-2 207391-44-4 207391-63-7
207391-64-8 207391-65-9 207391-67-1 207391-74-0 **219135-91-8**
219135-98-5 219136-10-4 **223445-75-8** 227625-35-6
227626-49-5 227626-51-9 230615-75-5 248275-68-5 248275-79-8
248275-81-2 248275-95-8 249296-44-4 287973-23-3 287973-26-6
287973-27-7 328055-76-1 328055-77-2 328055-78-3 328055-79-4
328055-80-7 328055-81-8 328055-83-0 328055-84-1 328055-85-2
328055-86-3 328055-87-4 328055-88-5 328055-89-6 328055-90-9
328055-92-1 328055-94-3 328055-95-4 328055-96-5 328055-97-6
328055-98-7 328055-99-8 328056-00-4 328056-01-5 328056-02-6
328056-03-7 328056-04-8 328056-05-9 328056-06-0 328056-07-1
328056-08-2 328056-09-3 328056-10-6 328056-11-7 328056-12-8
328056-13-9 328056-14-0 328056-15-1 328056-16-2 328056-17-3
328056-18-4 328056-19-5 328056-20-8 328056-21-9 328056-22-0
328056-23-1 328056-24-2 328056-25-3 328056-26-4 328056-27-5
328056-28-6 328056-66-2 335458-65-6 335458-69-0 357424-19-2
357424-20-5 415682-84-7 473924-33-3 610300-06-6 610300-07-7
610300-11-3 610300-12-4 610300-17-9 610300-18-0 610300-19-1
610300-20-4 610300-21-5 610300-22-6 610300-23-7 610300-24-8
610300-25-9 610300-26-0 610300-27-1 610300-28-2 610300-29-3
610300-30-6 610300-31-7 610300-32-8 610300-33-9 610300-34-0
641635-01-0 658683-13-7 658683-30-8 658683-32-0 658683-33-1
658683-34-2 658683-35-3 663623-18-5 663623-19-6 663623-20-9
663623-21-0 663623-22-1 663623-23-2 663623-24-3 663623-25-4
663623-26-5 663623-27-6 663623-28-7 663623-29-8 663623-31-2
663623-35-6 663623-36-7 663623-37-8 663623-38-9 663623-39-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic receptor partial agonist-α2δ ligand combination for prevention and treatment of addiction)

IT **219135-91-8 219135-98-5 223445-75-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic receptor partial agonist-α2δ ligand combination for prevention and treatment of addiction)

RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:17019 CAPLUS
DOCUMENT NUMBER: 142:107448
TITLE: Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
INVENTOR(S): Roark, William Howard
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005004177	A1	20050106	US 2004-883899	20040702
WO 2005002585	A1	20050113	WO 2004-IB2075	20040621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-484577P P 20030702
OTHER SOURCE(S): MARPAT 142:107448

ED Entered STN: 09 Jan 2005
AB This invention relates to a combination of an allosteric inhibitor of matrix metalloproteinase-13 (MMP-13), or a pharmaceutically acceptable salt thereof, and a ligand to an alpha-2-delta receptor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the combination, and a method of using the combination to treat a disease or disorder in a mammal responsive to treatment in one aspect by an allosteric inhibitor of MMP-13 and in the same or a different aspect by a ligand to an alpha-2-delta receptor, such as cartilage damage and joint diseases. Preparation of 4-[[3-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoylamino]methyl]benzoic acid as the allosteric inhibitor of MMP-13 is exemplified.
IC ICM A61K031-4439
ICS A61K031-41
INCL 514341000; 514381000
CC 1-12 (Pharmacology)
Section cross-reference(s): 27, 28, 63
IT **223445-75-8P** 227625-35-6P 227626-51-9P 313651-33-1P
335458-65-6P 473924-33-3P 610300-07-7P 610300-19-1P 610300-20-4P
658081-96-0P 660858-61-7P 660858-62-8P 660858-63-9P 660858-64-0P
660858-65-1P 660858-66-2P 660858-67-3P 660858-68-4P 660858-69-5P
660858-70-8P 660858-71-9P 660858-72-0P 660858-73-1P 660858-74-2P
660858-75-3P 660858-76-4P 660858-77-5P 660858-78-6P 660858-79-7P
660858-80-0P 660858-81-1P 660858-82-2P 660858-83-3P 660858-84-4P
660858-86-6P 660858-87-7P 660858-88-8P 660858-89-9P 660858-90-2P
660858-92-4P 660858-96-8P 660858-98-0P 660859-04-1P 660859-05-2P
660859-09-6P 661485-66-1P 724707-68-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
IT **223445-75-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965255 CAPLUS
DOCUMENT NUMBER: 141:410950
TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 279 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004096810	A1	20041111	WO 2004-IB1433		20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004234158	A1	20041111	AU 2004-234158		20040422
CA 2523831	AA	20041111	CA 2004-2523831		20040422
EP 1620437	A1	20060201	EP 2004-728868		20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004009903	A	20060425	BR 2004-9903		20040422
NL 1026074	A1	20041101	NL 2004-1026074		20040428
NL 1026074	C2	20050809			
US 2005043325	A1	20050224	US 2004-834484		20040429
NO 2005004404	A	20051124	NO 2005-4404		20050922
PRIORITY APPLN. INFO.:			GB 2003-9780	A	20030429
			GB 2003-27748	A	20031128
			US 2003-476678P	P	20030606
			US 2004-538147P	P	20040120
			WO 2004-IB1433	A	20040422

OTHER SOURCE(S): MARPAT 141:410950
ED Entered STN: 12 Nov 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.
IC ICM C07D487-04
ICS A61K031-505; A61K031-519
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 50-78-2, Aspirin 52-01-7, Spironolactone 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 77-36-1, Chlorothalidone 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 2609-46-3, Amiloride 3930-20-9, Sotalol 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 26839-75-8, Timolol 29094-61-9, Glipizide 29122-68-7, Atenolol 51384-51-1, Metoprolol 56211-40-6, Torsemide 60142-96-3, Gabapentin 72956-09-3, Carvedilol 74191-85-8, Doxazosin 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 81093-37-0, Pravastatin 85441-61-8, Quinapril 87333-19-5, Ramipril 88150-42-9, Amlodipine 93479-97-1, Glimepiride 107724-20-9, Eplerenone 111025-46-8, Pioglitazone 114798-26-4, Losartan 122320-73-4, Rosiglitazone 133040-01-4, Eprosartan 134523-00-5, Atorvastatin 137862-53-4, Valsartan 138402-11-6, Irbesartan 139481-59-7, Candesartan 144701-48-4, Telmisartan 148553-50-8, Pregabalin 209789-08-2, CI 1027 227625-35-6, 3-[1-(Aminomethyl)cyclohexylmethyl]-4H-[1,2,4]oxadiazol-5-one 227626-51-9, [[[1-(1H-Tetrazol-5-ylmethyl)cycloheptyl]methyl]amine 287714-41-4, Rosuvastatin 313651-33-1, (3S,5R)-3-Aminomethyl-5-methyloctanoic acid 335458-65-6 473924-33-3 610300-07-7, (3S,5R)-3-Amino-5-methyloctanoic acid 610300-19-1, (3S,5R)-3-Amino-5-methylheptanoic acid 610300-20-4, (3S,5R)-3-Amino-5-methylnonanoic acid **772324-47-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

IT **772324-47-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 772324-47-7 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:531356 CAPLUS

DOCUMENT NUMBER: 141:65106

TITLE: Calcium channel α-2-δ subunit ligands to treat chronic obstructive pulmonary disease (COCD), chronic cough, and other diseases

INVENTOR(S): Bertrand, Claude Philippe; Chovet, Maria Emilia Pereira Chicau; Geppetti, Pierangelo; Taylor, Charles Price, Jr.; Thorpe, Andrew John; Wustrow, David Juergen

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004054577	A1	20040701	WO 2003-IB5640		20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2451267	AA	20040613	CA 2003-2451267		20031127
US 2004176456	A1	20040909	US 2003-726878		20031202
AU 2003303037	A1	20040709	AU 2003-303037		20031203
CN 1726015	A	20060125	CN 2003-80105968		20031203
CN 1726021	A	20060125	CN 2003-80106009		20031203
US 2004132636	A1	20040708	US 2003-731605		20031209
US 2004180958	A1	20040916	US 2003-732613		20031210
US 2004143014	A1	20040722	US 2003-735398		20031212
PRIORITY APPLN. INFO.:			US 2002-433491P	P	20021213
			GB 2003-2657	A	20030205
			US 2003-454074P	P	20030312
			WO 2003-IB5640	W	20031203

OTHER SOURCE(S): MARPAT 141:65106
ED Entered STN: 02 Jul 2004
AB The invention discloses the use of an calcium channel α-2-δ subunit ligand in the treatment of chronic obstructive pulmonary disease (COPD) and diseases associated with a diagnosis of COPD, and particularly to the treatment of chronic cough, which may be unrelated to COPD. Compound preparation is included.
IC ICM A61K031-4245
ICS A61K031-195; A61K031-197; A61K031-401; A61P011-00; A61P011-14
CC 1-9 (Pharmacology)
Section cross-reference(s): 27
IT 60142-96-3, Gabapentin **223445-75-8** 227625-35-6 313651-33-1 335458-65-6 473924-33-3 610300-07-7 610300-19-1 610300-20-4 686766-42-7 688007-58-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel α-2-δ subunit ligands to treat chronic obstructive pulmonary disease, chronic cough, and other diseases)
IT **223445-75-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel α-2-δ subunit ligands to treat chronic obstructive pulmonary disease, chronic cough, and other diseases)
RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531343 CAPLUS
DOCUMENT NUMBER: 141:82343
TITLE: Gabapentin analogues for fibromyalgia and other related disorders
INVENTOR(S): Dooley, David James; Taylor, Charles Price, Jr.; Thorpe, Andrew John; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004054564	A1	20040701	WO 2003-IB5710		20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2509615	AA	20040701	CA 2003-2509615		20031203
AU 2003283718	A1	20040709	AU 2003-283718		20031203
EP 1572184	A1	20050914	EP 2003-775699		20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016751	A	20051025	BR 2003-16751		20031203
CN 1720038	A	20060111	CN 2003-80104702		20031203
JP 2006511605	T2	20060406	JP 2005-502470		20031203
US 2004180958	A1	20040916	US 2003-732613		20031210
US 2004180959	A1	20040916	US 2003-735561		20031212
PRIORITY APPLN. INFO.:			US 2002-433491P	P	20021213
			US 2003-483435P	P	20030627
			GB 2003-2657	A	20030205
			US 2003-454074P	P	20030312
			WO 2003-IB5710	W	20031203

OTHER SOURCE(S): MARPAT 141:82343
ED Entered STN: 02 Jul 2004
GI



I



II

AB This invention discloses the method for treating fibromyalgia and other disorders in a mammal, including a human, comprising administration of a therapeutically effective amount of a compds. of Formula I or Formula II (where R1 - R14 = H, (un)branched C1-C6 alkyl, ph, OH, etc., and R1 - R8 are not simultaneously H) or a pharmaceutically acceptable salt thereof.

IC ICM A61K031-195
ICS A61P025-18; A61P043-00

CC 1-11 (Pharmacology)
Section cross-reference(s): 24

IT **223425-82-9P 223425-83-0P 223425-85-2P**
223445-66-7P 223445-67-8P 713079-21-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(gabapentin analogs for fibromyalgia and other related disorders)

IT 27741-65-7P 198132-54-6P 223425-55-6P 223425-58-9P 223425-65-8P
223425-67-0P 223425-68-1P 223425-69-2P 223425-70-5P 223425-71-6P
223425-75-0P 223425-79-4P 223425-80-7P **223425-81-8P**
223445-59-8P 223445-60-1P 260983-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(gabapentin analogs for fibromyalgia and other related disorders)

IT **223445-68-9P** 714264-60-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(gabapentin analogs for fibromyalgia and other related disorders)

IT **223425-82-9P 223425-83-0P 223425-85-2P**
223445-66-7P 223445-67-8P 713079-21-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(gabapentin analogs for fibromyalgia and other related disorders)

RN 223425-82-9 CAPLUS

CN Cyclobutaneacetic acid, 1-(aminomethyl)-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 223425-83-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (3R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 223425-85-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-dimethyl-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 223445-66-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride,
(3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 223445-67-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride,
(3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 713079-21-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **223425-75-0P 223425-81-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(gabapentin analogs for fibromyalgia and other related disorders)
RN 223425-75-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, ethyl ester, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-81-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT **223445-68-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(gabapentin analogs for fibromyalgia and other related disorders)
RN 223445-68-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531342 CAPLUS
DOCUMENT NUMBER: 141:88858
TITLE: A preparation of aminocarboxylic acid derivatives as alpha-2-delta ligands, useful for the treatment of sexual dysfunction
INVENTOR(S): Taylor, Charles Price, Jr; Thorpe, Andrew John; Van Der Graaf, Pieter Hadewijn; Wayman, Christopher Peter; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054563	A1	20040701	WO 2003-IB5682	20031203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2451267	AA	20040613	CA 2003-2451267		20031127
US 2004176456	A1	20040909	US 2003-726878		20031202
CA 2509611	AA	20040701	CA 2003-2509611		20031203
AU 2003283708	A1	20040709	AU 2003-283708		20031203
EP 1572183	A1	20050914	EP 2003-775689		20031203

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003016753	A	20051025	BR 2003-16753		20031203
CN 1726015	A	20060125	CN 2003-80105968		20031203
CN 1726021	A	20060125	CN 2003-80106009		20031203
US 2004132636	A1	20040708	US 2003-731605		20031209
US 2004180958	A1	20040916	US 2003-732613		20031210
US 2004143014	A1	20040722	US 2003-735398		20031212
PRIORITY APPLN. INFO.:			US 2002-433491P	P	20021213
			GB 2003-2657	A	20030205
			US 2003-454074P	P	20030312
			WO 2003-IB5682	W	20031203

OTHER SOURCE(S): MARPAT 141:88858
ED Entered STN: 02 Jul 2004
GI



I



II

AB The invention relates to a preparation of aminocarboxylic acid derivs., e.g. I [wherein: R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from H or C1-6alkyl, or R8 and R6 or R6 and R4 are taken together to form C3-7 cycloalkyl ring, etc.; n = 0-2; X is a carboxylic acid or carboxylic acid bioisostere], as alpha-2-delta ligands, useful for the treatment of premature ejaculation. For instance, delayed ejaculation in the presence of alpha-2-delta ligand II and effect of compound II on copulatory behavior in rapid ejaculating rats were demonstrated. Compound II increased ejaculation latency by 58% in rapidly ejaculating conscious rats.

IC ICM A61K031-195
ICS A61K031-197; A61K031-4015; A61P015-00

CC 23-16 (Aliphatic Compounds)
Section cross-reference(s): 1, 63

IT 60142-96-3P, Gabapentin 148553-50-8P **219135-98-5P**
227625-35-6P 227626-51-9P 313651-33-1P 473829-37-7P 473829-38-8P
473829-39-9P 473829-40-2P 473829-41-3P 473829-42-4P 473829-43-5P
473829-44-6P 473829-45-7P 473829-46-8P 473924-33-3P 473924-35-5P
610300-19-1P 686766-30-3P 686766-32-5P 686766-36-9P 686766-42-7P
686766-43-8P 686766-87-0P 688007-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocarboxylic acid derivs. as alpha-2-delta ligands, useful for the treatment of sexual dysfunction)

IT **219135-98-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocarboxylic acid derivs. as alpha-2-delta ligands, useful for the treatment of sexual dysfunction)

RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531340 CAPLUS
DOCUMENT NUMBER: 141:89004
TITLE: Use of alpha-2-delta ligands to treat lower urinary tract symptoms associated with overactive bladder or benign prostatic hyperplasia, and the preparation of 4-substituted pyrrolidine-2-carboxylic acid derivatives and other compounds as ligands for such use
INVENTOR(S): Taylor, Charles Price, Jr.; Thorpe, Andrew John; Westbrook, Simon Lempriere; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054560	A1	20040701	WO 2003-IB5729	20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509605	AA	20040701	CA 2003-2509605	20031203
AU 2003303041	A1	20040709	AU 2003-303041	20031203

EP 1572173	A1	20050914	EP 2003-813233		20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016572	A	20051004	BR 2003-16572		20031203
CN 1720029	A	20060111	CN 2003-80105291		20031203
JP 2006511606	T2	20060406	JP 2005-502472		20031203
US 2004180958	A1	20040916	US 2003-732613		20031210
NO 2005003355	A	20050711	NO 2005-3355		20050711
PRIORITY APPLN. INFO.:			US 2002-433491P	P	20021213
			GB 2003-2657	A	20030205
			US 2003-454074P	P	20030312
			WO 2003-IB5729	W	20031203

OTHER SOURCE(S): MARPAT 141:89004
ED Entered STN: 02 Jul 2004
GI



I

AB Disclosed is the use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of lower urinary tract symptoms (LUTS), other than urinary incontinence, which are associated with overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH). Such use of approx. 35 specific compds. and/or their derivs. is claimed. For instance, (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu 2-Me ester was etherified with 3-chlorophenol under Mitsunobu conditions (86%), followed by saponification of the Me ester with LiOH in aqueous THF (98%), and hydrolysis of the tert-Bu ester with HCl in dioxane/THF (86.7%), to give acid I, a use-claimed ligand, as the HCl salt, on a 7-kg scale. In tests of gabapentin, a well-known alpha-2-delta ligand, on the micturition reflex of anesthetized rats, a significant, dose-dependent increase in interval between voiding episodes was observed relative to control animals, with a reduction in voids per h from approx. 5 to <1.

IC ICM A61K031-00
ICS A61K031-197; A61P013-00; A61K031-195

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

IT 60142-95-2, Gabapentin hydrochloride 60142-96-3, Gabapentin 148553-50-8, Pregabalin **219135-98-5** 227625-35-6 227626-51-9 313651-33-1 335458-65-6 335458-65-6D, derivs. 335671-52-8D, derivs. 335671-53-9D, derivs. 335671-55-1D, derivs. 473829-37-7 473829-38-8 473829-39-9 473829-40-2 473829-41-3 473829-42-4 473829-43-5 473829-44-6 473829-45-7 473829-46-8 473924-33-3 473924-35-5 663178-19-6D, derivs. 663178-21-0D, derivs. 663178-24-3D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug use candidate; preparation of alpha-2-delta ligands to treat lower urinary tract symptoms)

IT **219135-98-5**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug use candidate; preparation of alpha-2-delta ligands to treat lower urinary tract symptoms)
RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162588 CAPLUS
DOCUMENT NUMBER: 140:210798
TITLE: Synergistic combination of an α2δ ligand and a PDEV inhibitor for use in the treatment of pain
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004016259	A1	20040226	WO 2003-IB3476		20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2495433	AA	20040226	CA 2003-2495433		20030804
AU 2003249476	A1	20040303	AU 2003-249476		20030804
EP 1536782	A1	20050608	EP 2003-787957		20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013484	A	20050621	BR 2003-13484		20030804
JP 2006502139	T2	20060119	JP 2004-528754		20030804
US 2004092591	A1	20040513	US 2003-640547		20030813
NO 2005000782	A	20050408	NO 2005-782		20050214
PRIORITY APPLN. INFO.:			GB 2002-19024	A	20020815
			GB 2002-23067	A	20021004
			US 2002-421866P	P	20021028
			WO 2003-IB3476	W	20030804

ED Entered STN: 29 Feb 2004
AB The invention relates to a combination of an α2δ ligand and a PDEV inhibitor for use in therapy, particularly in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain. Particularly preferred α2δ α2δ α2δ ligands are gabapentin and pregabalin. Particularly preferred PDEV inhibitors are sildenafil, vardenafil and tadalafil. Combinations of gabapentin and sildenafil on CCI-induced allodynia showed synergic effects over those effects with the drugs administered alone. (3S,5R)-3-amino-5-methyloctanoic acid was prepared as an example of an α2δ ligand.
IC ICM A61K031-195
ICS A61K031-197; A61K031-522; A61K031-4985; A61K031-53; A61P025-00; A61P025-02
CC 1-11 (Pharmacology)
Section cross-reference(s): 23, 24, 28, 63
IT **223445-75-8P** 227625-35-6P 227626-51-9P 313651-33-1P
335458-65-6P 473924-33-3P 610300-02-2P 610300-05-5P 610300-06-6P
610300-07-7P 610300-08-8P 610300-10-2P 610300-11-3P 610300-13-5P
610300-14-6P 610300-15-7P 610300-19-1P 610300-20-4P 610300-30-6P
663920-78-3P 663920-98-7P 663920-99-8P 664345-46-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synergistic combination of an α2δ ligand and a PDEV inhibitor for use in the treatment of pain)
IT **223445-75-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synergistic combination of an α2δ ligand and a PDEV inhibitor for use in the treatment of pain)
RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:60177 CAPLUS
DOCUMENT NUMBER: 140:128685
TITLE: Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
INVENTOR(S): Raillard, Stephen P.; Zhou, Cindy X.; Yao, Fenmei; Manthati, Suresh Kumar; Xiang, Jia-ning; Gallop, Mark A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 171,485.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004014940	A1	20040122	US 2003-460091	20030611
US 2003176398	A1	20030918	US 2002-171485	20020611
US 6818787	B2	20041116		
ZA 2003009679	A	20041222	ZA 2003-9679	20020611
US 2004006132	A1	20040108	US 2003-459242	20030610
US 6972341	B2	20051206		
WO 2003104184	A1	20031218	WO 2003-US18495	20030611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003247522	A1	20031222	AU 2003-247522	20030611
EP 1554237	A1	20050720	EP 2003-757492	20030611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529941	T2	20051006	JP 2004-511254	20030611
ZA 2003009678	A	20050812	ZA 2003-9678	20031212
US 2004198820	A1	20041007	US 2004-829896	20040421

PRIORITY APPLN. INFO.:			
US 2001-297521P	P	20010611	
US 2001-298514P	P	20010614	
US 2002-366090P	P	20020319	
US 2002-171485	A2	20020611	
US 2002-170127	A1	20020611	
WO 2003-US18495	W	20030611	

OTHER SOURCE(S): CASREACT 140:128685; MARPAT 140:128685
ED Entered STN: 26 Jan 2004
AB The invention provides a method for synthesizing 1-(acyloxy)alkyl carbamates R1CO2CR2R3O2C(NR4CHR5CO)nNHCHR6CR7R8CHR9CO2R10 [n is 0 or 1; R1 is acyl or groups (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl, heteroarylalkyl (groups Q); R2, R3 are H, (un)substituted alkoxycarbonyl, carbamoyl or groups Q; or R2R3C is (un)substituted cycloalkyl or cycloheteroalkyl; R4 is H or groups Q; R5 is H, (un)substituted alkoxy, acyl, carbamoyl or groups Q; or R4R5C is (un)substituted cycloheteroalkyl; R6, R9 are H or groups Q; R7, R8 are H, (un)substituted acyl or groups Q except aryl; or R7R8C is (un)substituted cycloalkyl, cycloheteroalkyl or bridged cycloalkyl; R10 is H, aryldialkylsilyl, trialkylsilyl, or groups Q] of GABA analogs from 1-haloalkyl carbamates XCR2R3O2C(NR4CHR5CO)nNHCHR6CR7R8CHR9CO2R10 (X is F, Cl, Br, or I). Thus, gabapentin (a GABA analog) was converted into benzyl 1-[[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl]cyclohexaneacetate by esterification with benzyl alc., acylation with 1-chloroethyl chloroformate, and esterification with isobutyric acid.
IC ICM C07K001-04
ICS C07C271-10; C07D213-55
INCL 530332000; 560041000; 546335000; 560024000; 560159000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
IT **60142-99-6** 194862-79-8 194862-80-1 196608-53-4 196608-58-9

196608-60-3 196608-62-5 206749-40-8 206749-41-9 206749-42-0
219135-91-8 219135-98-5 271580-09-7 271580-10-0
313651-01-3, 3-Aminomethyl-5-methyl-heptanoic acid; 313651-02-4,
3-Aminomethyl-5-methyl-octanoic acid 313651-03-5 313651-04-6
313651-08-0 313651-09-1 313651-10-4 313651-11-5 313651-13-7
478297-20-0 478297-21-1 478297-22-2 478297-23-3 478297-24-4
478297-25-5 478297-26-6 478297-27-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog; synthesis of acyloxyalkyl derivs. of GABA analogs)

IT **60142-99-6 219135-91-8 219135-98-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog; synthesis of acyloxyalkyl derivs. of GABA analogs)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41129 CAPLUS
DOCUMENT NUMBER: 140:99631
TITLE: Gastrointestinal compositions containing GABA analogs
INVENTOR(S): Ciociola, Arthur A.; Segal, Catherine A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004010035	A1	20040115	US 2002-196060	20020715
CA 2491721	AA	20040122	CA 2003-2491721	20030630
WO 2004006901	A1	20040122	WO 2003-IB3156	20030630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003247042	A1	20040202	AU 2003-247042	20030630
BR 2003012568	A	20050503	BR 2003-12568	20030630
EP 1549302	A1	20050706	EP 2003-764069	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533100	T2	20051104	JP 2004-521018	20030630
PRIORITY APPLN. INFO.:			US 2002-193640 A	20020710
			US 2002-196060 A	20020715
			WO 2003-IB3156 W	20030630

OTHER SOURCE(S): MARPAT 140:99631
ED Entered STN: 18 Jan 2004
AB The invention relates to compns. and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders. A gelatin capsule comprised gabapentin 20.000, trimebutine 20.000, lactose 5.000, and tricalcium phosphate 55.000%.
IC ICM A61K031-21
INCL 514506000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 51-77-4, Gefarnate 56-12-2D, GABA, analogs 56-81-5, Glycerin, biological studies 60-54-8, Tetracycline 67-20-9, Nitrofurantoin 84-65-1D, Anthraquinone, derivs. 101-81-5D, Diphenylmethane, derivs. 128-49-4, Dioctyl calcium sulfosuccinate 154-23-4, Catechin 364-62-5, Metoclopramide 489-84-9, Guaiazulene 577-11-7, Dioctyl sodium sulfosuccinate 1222-57-7, Zolimidine 1309-42-8, Magnesium hydroxide 1397-74-6, Acetyltannic acid 1406-05-9, Penicillin 5697-56-3, Carbenoxolone 6277-14-1, Acetoxolone 6809-52-5, Teprenone 6998-60-3, Rifamycin 7487-88-9, Magnesium sulfate, biological studies 7491-09-0, Dioctyl potassium sulfosuccinate 7527-94-8, Alkofanone 7558-79-4, Dibasic sodium phosphate 7558-80-7, Monobasic sodium phosphate 7779-25-1, Magnesium citrate 9003-97-8, Polycarbophil 9004-32-4, Carboxymethyl cellulose sodium 9004-67-5, Methyl cellulose 9007-67-4, Enterogastrone 11042-64-1, γ-Oryzanol 11111-12-9, Cephalosporin 12607-92-0, Aceglutamide aluminum 15479-57-9, Aluminum salicylate 19368-18-4, Ftaxilide 20231-81-6, Uzarin 23910-07-8, Mebiquine 28797-61-7, Pirenzepine 30751-05-4, Troxipide 34675-84-8, Cetraxate 36877-68-6, Nitroimidazole 39133-31-8, Trimebutine 51481-61-9, Cimetidine 54182-58-0, Sucralfate 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 55028-70-1, Arbaprostil 56208-01-6, Pifarnine 56695-65-9, Rosaprostol 57381-26-7, Irsogladine 57644-54-9, Bismuth subcitrate 57808-66-9, Domperidone 60142-96-3, Gabapentin 61869-08-7, Paroxetine 64204-55-3, Esaprazole 64218-02-6, Plaunotol 64506-49-6, Sofalcone 66357-35-5, Ranitidine 66871-56-5, Lidamidine 69900-72-7, Trimoprostil 70667-26-4, Ornoprostil 72492-12-7,

Spizofurone 73121-56-9, Enprostil 73590-58-6, Omeprazole 76824-35-6, Famotidine 76963-41-2, Nizatidine 77287-05-9, Rioprostil 78628-28-1, Roxatidine acetate 78718-25-9, Benexate hydrochloride 79617-96-2, Sertraline 80738-43-8, Lincosamide 81098-60-4, Cisapride 83150-76-9, Octreotide 92071-51-7, Rotraxate 99614-02-5, Ondansetron 112727-80-7, Renzapride 120635-74-7, Cilansetron 122852-42-0, Alosetron 123618-00-8, Fedotozine 126040-58-2, Calcium polycarbophil 128013-69-4 148553-50-8 196608-53-4 **219135-91-8** **219135-98-5** 219136-10-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (gastrointestinal compns.)

IT **219135-91-8 219135-98-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (gastrointestinal compns.)

RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41128 CAPLUS
DOCUMENT NUMBER: 140:99630
TITLE: Gastrointestinal compositions containing GABA analogs
INVENTOR(S): Ciociola, Arthur A.; Segal, Catherine A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004010034	A1	20040115	US 2002-193640	20020710
CA 2491721	AA	20040122	CA 2003-2491721	20030630
WO 2004006901	A1	20040122	WO 2003-IB3156	20030630

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003247042	A1	20040202	AU 2003-247042	20030630
BR 2003012568	A	20050503	BR 2003-12568	20030630
EP 1549302	A1	20050706	EP 2003-764069	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533100	T2	20051104	JP 2004-521018	20030630
PRIORITY APPLN. INFO.:			US 2002-193640	A 20020710
			US 2002-196060	A 20020715
			WO 2003-IB3156	W 20030630

OTHER SOURCE(S): MARPAT 140:99630
ED Entered STN: 18 Jan 2004
AB The invention relates to compns. and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders. Thus, capsules contained gabapentin 20.000, trimebutine 20.000, lactose, 5.000, and tricalcium phosphate 55.000%.
IC ICM A61K031-21
INCL 514506000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 51-77-4, Gefarnate 56-12-2D, GABA, analogs 56-81-5, Glycerin, biological studies 60-54-8, Tetracycline 61-33-6, biological studies 67-20-9, Nitrofurantoin 84-65-1D, Anthraquinone, derivs. 101-81-5D, Diphenylmethane, derivs. 128-49-4, Dioctyl calcium sulfosuccinate 154-23-4, Catechin 364-62-5, Metoclopramide 489-84-9, Guaiazulene 577-11-7, Dioctyl sodium sulfosuccinate 1222-57-7, Zolimidine 1309-42-8, Magnesium hydroxide 1397-74-6, Acetyltannic acid 5697-56-3, Carbenoxolone 6277-14-1, Acetoxolone 6809-52-5, Teprenone 6998-60-3, Rifamycin 7487-88-9, Magnesium sulfate, biological studies 7491-09-0, Dioctyl potassium sulfosuccinate 7527-94-8, Alkofanone 7558-79-4, Dibasic sodium phosphate 7558-80-7, Monobasic sodium phosphate 7779-25-1, Magnesium citrate 9004-32-4, Carboxymethyl cellulose sodium 9004-67-5, Methyl cellulose 9007-67-4, Enterogastrone 11042-64-1, .γ.-Oryzanol 11111-12-9, Cephalosporin 12607-92-0, Aceglutamide aluminum 15479-57-9, Aluminum salicylate 19368-18-4, Ftaxilide 20231-81-6, Uzarin 23910-07-8, Mebiquine 28797-61-7, Pirenzepine 30751-05-4, Troxipide 34675-84-8, Cetraxate 36877-68-6D, Nitroimidazole, derivs. 39133-31-8, Trimebutine 51481-61-9, Cimetidine 53908-04-6D, Penam, derivs. 54182-58-0, Sucralfate 55028-70-1, Arbaprostil 56208-01-6, Pifarnine 56695-65-9, Rosaprostol 57381-26-7, Irsogladine 57644-54-9, Bismuth subcitrate 57808-66-9, Domperidone 60142-96-3, Gabapentin 64204-55-3, Esaprazole 64218-02-6, Plaunotol 64506-49-6, Sofalcone 66357-35-5, Ranitidine 66871-56-5, Lidamidine 69900-72-7, Trimoprostil 70020-71-2, ε-Acetamidocaproic acid zinc salt 70667-26-4, Ornoprostil 72492-12-7, Spizofurone 73121-56-9, Enprostil 73590-58-6, Omeprazole 76824-35-6, Famotidine 76963-41-2, Nizatidine 77287-05-9, Rioprostil 78628-28-1, Roxatidine acetate 78718-25-9, Benexate hydrochloride 80738-43-8, Lincosamide 81098-60-4, Cisapride 83150-76-9, Octreotide 92071-51-7, Rotraxate 99614-02-5, Ondansetron 122852-42-0, Alosetron 123618-00-8, Fedotozine 128013-69-4 148553-50-8 179474-81-8, Prucalopride 196608-53-4 **219135-91-8 219135-98-5** 219136-10-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gastrointestinal compns. containing GABA analogs)
IT **219135-91-8 219135-98-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gastrointestinal compns. containing GABA analogs)
RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:678656 CAPLUS
DOCUMENT NUMBER: 139:202522
TITLE: Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
INVENTOR(S): Taylor, Charles Price, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070237	A1	20030828	WO 2003-IB534	20030212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476438	AA	20030828	CA 2003-2476438	20030212
AU 2003246864	A1	20030909	AU 2003-246864	20030212
EP 1480639	A1	20041201	EP 2003-742460	20030212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2003007906	A	20041221	BR 2003-7906		20030212
CN 1635887	A	20050706	CN 2003-804356		20030212
JP 2005523281	T2	20050804	JP 2003-569193		20030212
US 2003199567	A1	20031023	US 2003-366798		20030214
NO 2004003947	A	20040921	NO 2004-3947		20040921
PRIORITY APPLN. INFO.:			US 2002-359295P	P	20020222
			US 2002-404365P	P	20020819
			WO 2003-IB534	W	20030212

ED Entered STN: 29 Aug 2003

AB The invention relates to a combination, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and a ligand for calcium channel α2δ subunit, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of α2δ ligands include gabapentin, pregabalin, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexymethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride (I). The combinations are useful for treating certain diseases including cartilage damage, inflammation, pain, and arthritis. For example, capsules containing 25 mg each of valdecoxib and I were prepared

IC ICM A61K031-42
ICS A61K031-195; A61K031-4245; A61P019-02

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT 60142-96-3, Gabapentin 148553-50-8, Pregabalin 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **223445-75-8** 227626-75-7 228104-34-5 335671-48-2 473924-33-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing combinations of ligand for calcium channel α2δ subunit with selective inhibitor of cyclooxygenase-2)

IT **223445-75-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing combinations of ligand for calcium channel α2δ subunit with selective inhibitor of cyclooxygenase-2)

RN 223445-75-8 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:610247 CAPLUS

DOCUMENT NUMBER: 139:164792

TITLE: Preparation of (1-aminomethyl-1-cycloalkyl)acetic acid derivatives and 4-aminobutanoic acid derivatives as alpha 2 delta ligands to treat tinnitus

INVENTOR(S): Dooley, David James; Wustrow, David Juergen

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003063845	A1	20030807	WO 2003-IB232		20030120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2474000	AA	20030807	CA 2003-2474000		20030120
EP 1469841	A1	20041027	EP 2003-700417		20030120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007411	A	20041207	BR 2003-7411		20030120
CN 1625393	A	20050608	CN 2003-803138		20030120
JP 2005521664	T2	20050721	JP 2003-563539		20030120
US 2003176504	A1	20030918	US 2003-353367		20030129
US 7026505	B2	20060411			
ZA 2004003069	A	20050422	ZA 2004-3069		20040422
US 2006100281	A1	20060511	US 2005-314126		20051221
PRIORITY APPLN. INFO.:			US 2002-353632P	P	20020131
			WO 2003-IB232	W	20030120
			US 2003-353367	A3	20030129

OTHER SOURCE(S): MARPAT 139:164792
ED Entered STN: 08 Aug 2003
GI



I

AB The invention relates to a method of treating tinnitus by administering an α2δ [α2δ subunit of presynaptic P/Q-type voltage-sensitive Ca2+ channels (VSCC)] ligand such as, for example, a compound of formula (I; R1 = H, straight or branched lower alkyl; n = an integer of 4-6) or γ-aminobutyric acid derivs. represented by formula H2NCH(R3)CR1R2CH2CO2H [R1 = straight or branched unsubstituted C1-6 alkyl, unsubstituted Ph, unsubstituted C3-6 cycloalkyl; R2 = H, Me; R3 = H, Me, CO2H] and pharmaceutically acceptable salts thereof. Thus, NaH (60% dispersion, 2.4 g, 65 mmol) was washed with hexane, suspended in 60 mL dimethoxyethane, slowly treated with tri-Et phosphonoacetate over 5 min under ice-cooling in ice water bath was slowly added, stirred for 15 min at 0°, treated with a solution of 3-methyl-1-pentanal (6.5 g, 65 mmol) 20 mL in methoxyethane, and refluxed overnight to give, after

workup, Et 61% 5-methyl-2-heptenoate (II). II 6.75, DBU 6.0, and MeNO2 21.97 g were stirred in 80 mL MeCN overnight under N to give, after workup, 42% Et 5-methyl-3-nitromethylheptanoate (III). III (3.6 g) was hydrogenated in the presence of 20% Pd-C in ethanol to give Et 3-aminomethyl-5-methylheptanoic acid which was refluxed in 30 mL 6 N aqueous HCl overnight to give, after purification on a column of Dowex 50WX8-100 ion exchange resin, 630 mg 3-aminomethyl-5-methylheptanoic acid. A tablet, a coated tablet, in injection vial, and a suppository formulation, e.g. a tablet containing 3-[(1-aminomethylcyclohexyl)methyl]-4H-[1,2,4]oxdiazol-5-one hydrochloride, were prepared

IC ICM A61K031-00
ICS A61P027-16; A61K031-13; A61K031-131; A61K031-137; A61K031-4245; A61K031-41; A61K031-662; A61K031-18; A61K031-443

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 23, 24, 25, 63

IT 208836-20-8P, (R)-2,6-Dimethylnon-2-ene **223445-75-8P**
227625-02-7P, N-[2-(1-Aminomethylcyclohexyl)ethyl]methanesulfonamide
227625-03-8P, [(1-Aminomethylcyclohexyl)methyl]phosphonic acid
227625-04-9P, (2-Aminomethyl-4-methylpentyl)phosphonic acid
227625-05-0P, [[1-(1H-Tetrazol-5-ylmethyl)cyclohexyl]methyl]amine
227625-06-1P, 4-Methyl-2-(1H-tetrazol-5-ylmethyl)pentylamine
227625-35-6P, 3-[[1-(Aminomethyl)cyclohexyl]methyl]-4H-[1,2,4]oxadiazol-5-one 227626-51-9P, [[1-(1H-Tetrazol-5-ylmethyl)cycloheptyl]methyl]amine
227626-59-7P, N-[2-(1-(Nitromethyl)cyclohexyl)ethyl]acetamide
227626-72-4P, N-[2-(1-Aminomethylcyclohexyl)ethyl]methanesulfonamide hydrochloride 227626-73-5P, [[1-(1H-Tetrazol-5-ylmethyl)cyclohexyl]methyl]amine hydrochloride 227626-74-6P, N-[2-(1-Aminomethylcyclohexyl)ethyl]acetamide hydrochloride
227626-75-7P, 3-[(1-Aminomethylcyclohexyl)methyl]-4H-[1,2,4]oxadiazol-5-one hydrochloride 227626-76-8P, 3-[(1-Aminomethylcyclohexyl)methyl]-4H-[1,2,4]oxadiazole-5-thione hydrochloride 227626-77-9P, [[9-(1H-Tetrazol-5-ylmethyl)bicyclo[3.3.1]non-9-yl]methyl]amine hydrochloride 227626-78-0P, [[2-(1H-Tetrazol-5-ylmethyl)adamantan-2-yl]methyl]amine hydrochloride 227626-79-1P 228104-32-3P, 4-Methyl-2-(1H-tetrazol-5-ylmethyl)pentylamine hydrochloride
228104-33-4P, 3-(2-Aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazole-5-thione hydrochloride 228104-34-5P, 3-(2-Aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride 228104-35-6P, 3-(3-Amino-2-cyclopentylpropyl)-4H-[1,2,4]oxadiazol-5-one 228104-36-7P, 3-(3-Amino-2-cyclopentylpropyl)-4H-[1,2,4]thiadiazol-5-one 228104-37-8P
228104-38-9P, 3-(3-Amino-2-cyclobutylpropyl)-4H-[1,2,4]oxadiazol-5-one
228104-39-0P, 3-(3-Amino-2-cyclobutylpropyl)-4H-[1,2,4]thiadiazol-5-one
228104-40-3P, 2-Cyclobutyl-3-(2-oxo-2,3-dihydro-2λ4-[1,2,3,5]oxathiadiazol-4-yl)propylamine 313651-01-3P, 3-Aminomethyl-5-methylheptanoic acid 313651-02-4P, 3-Aminomethyl-5-methyloctanoic acid 313651-22-8P, (3R,4S)-3-Aminomethyl-4,5-dimethylhexanoic acid 313651-25-1P 313651-26-2P, 3-Aminomethyl-4-isopropylhexanoic acid 313651-28-4P, 3-Aminomethyl-4-isopropyloctanoic acid 313651-32-0P, (3S,5R)-3-Aminomethyl-5-methylheptanoic acid
313651-33-1P 313651-35-3P 313652-91-4P, 3-Aminomethyl-5,7-dimethyloctanoic acid 313652-94-7P 313652-99-2P 313653-05-3P
313653-08-6P 313653-15-5P, (3S,5R)-3-Aminomethyl-5-methyloctanoic acid hydrochloride 313653-29-1P, (3S,5S)-3-Aminomethyl-5-methyloctanoic acid
313653-36-0P, (3S,5S)-3-Aminomethyl-5-methylheptanoic acid 313653-43-9P, (3S,5R)-3-Aminomethyl-5-methylnonanoic acid hydrochloride 313653-47-3P, (3S,5S)-3-Aminomethyl-5-methylnonanoic acid 313653-64-4P 313653-77-9P, 3-Aminomethyl-4-isopropylheptanoic acid hydrochloride 335458-39-4P
335458-46-3P 335458-59-8P 335458-65-6P 335458-69-0P, (3-Aminomethylbicyclo[3.2.0]hept-3-yl)acetic acid 335458-85-0P
335458-87-2P 335458-88-3P 335458-89-4P 335458-91-8P 335458-92-9P

335458-93-0P 335458-94-1P 335458-95-2P 335458-96-3P 335458-98-5P
335459-01-3P 335459-03-5P 335459-05-7P 335459-07-9P 335459-09-1P
335459-11-5P 335459-13-7P 335459-15-9P 335459-21-7P 335459-25-1P
335459-27-3P 335459-29-5P 335671-40-4P 335671-43-7P 335671-48-2P
336106-40-2P 415682-84-7P, 3-[(1-Aminomethylcycloheptyl)methyl]-4H-[1,2,4]oxadiazol-5-one hydrochloride 577041-14-6P, 3-(2-Aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazole-5-thione 577041-15-7P, 3-(2-Aminomethyl-4-methylpentyl)-4H-[1,2,4]oxadiazol-5-one 577041-16-8P 577041-17-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (1-aminomethylcycloalkyl)acetic acid derivs. and 4-aminobutanoic acid derivs. as alpha 2 delta ligands for treating tinnitus)

IT **223445-75-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (1-aminomethylcycloalkyl)acetic acid derivs. and 4-aminobutanoic acid derivs. as alpha 2 delta ligands for treating tinnitus)

RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:964141 CAPLUS
DOCUMENT NUMBER: 138:24958
TITLE: Preparation of GABA analogs as prodrugs
INVENTOR(S): Gallop, Mark A.; Cundy, Kenneth C.; Zhou, Cindy X.; Yao, Fenmei; Xiang, Jia-Ning; Ollman, Ian R.; Qui, Fayang G.
PATENT ASSIGNEE(S): Xenoport, Inc., USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100347	A2	20021219	WO 2002-US18689	20020611
WO 2002100347	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2449729	AA	20021219	CA 2002-2449729		20020611
US 2003083382	A1	20030501	US 2002-170127		20020611
US 6833140	B2	20041221			
EP 1404324	A2	20040407	EP 2002-744314		20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 1533270	A	20040929	CN 2002-814583		20020611
JP 2004536873	T2	20041209	JP 2003-516067		20020611
ZA 2003009679	A	20041222	ZA 2003-9679		20020611
NZ 530109	A	20050624	NZ 2002-530109		20020611
CN 1753673	A	20060329	CN 2002-814572		20020611
ZA 2003009678	A	20050812	ZA 2003-9678		20031212
US 2004198820	A1	20041007	US 2004-829896		20040421
PRIORITY APPLN. INFO.:			US 2001-297521P	P	20010611
			US 2001-298514P	P	20010614
			US 2002-366090P	P	20020319
			US 2002-170127	A1	20020611
			WO 2002-US18689	W	20020611

OTHER SOURCE(S): MARPAT 138:24958
ED Entered STN: 20 Dec 2002
AB The invention provides prodrugs of GABA analogs and pharmaceutical compns. containing these prodrugs for treating or preventing common diseases and/or disorders. Compds. of formulas R1(X-CHR2CO)nNHCHR3CR4R5CHR6CO-Y-R7 [n = 0 or 1; X = O or an imino group; Y = O or S; R1 = (thio)acyl or phosphoryl groups, alkylthio, arylthio, etc.; R2-R7 = H, (cyclo)alkyl, aryl, etc.; CR4R5 = (un)substituted cyclo(hetero)alkyl, bridged cycloalkyl], R20R21C:(NCHR2CO)t(X-CHR2CO)uNHCHR3CR4R5CHR6CO-Y-R7 [t, u = 0 or 1; R20, R21 = groups similar to R4 and R5] , and R1(X-CHR2CO)nNRCHR3CR4R5CHR6CO-R [R2 = CR22R23O (to form a lactone), where R22, R23 are groups similar to R4 and R5] are claimed. Thus, 1-[[[[(pivaloyloxy)methoxy]carbonyl]amino]methyl]-1-cyclohexaneacetic acid (51) was prepared by acylation of gabapentin with p-nitrophenyl pivaloyloxymethyl carbonate (preparation given). In vitro Caco-2 cellular permeabilities of the prodrugs were determined, with compound 51 having Papp (apical to basolateral) and Papp (basolateral to apical) values of 1.06x10-4 and 1.25x10-5 cm/s, resp.
IC ICM A61K
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
IT 56-12-2DP, Gaba, analogs **60142-99-6P** 128013-69-4P
194862-79-8P 194862-80-1P 196608-53-4P 196608-58-9P 196608-60-3P
196608-62-5P 206749-40-8P 206749-41-9P 206749-42-0P
219135-91-8P 219135-98-5P 271580-09-7P 271580-10-0P
313651-01-3P 313651-02-4P 313651-03-5P 313651-04-6P 313651-08-0P
313651-09-1P 313651-10-4P 313651-11-5P 313651-13-7P 374622-34-1P
478296-56-9P 478296-57-0P 478296-60-5P 478296-61-6P 478296-62-7P
478296-64-9P 478296-65-0P 478296-66-1P 478296-67-2P 478296-68-3P
478296-71-8P 478296-72-9P 478296-73-0P 478296-74-1P 478296-75-2P
478296-76-3P 478296-77-4P 478296-78-5P 478296-79-6P 478296-80-9P
478296-81-0P 478296-82-1P 478296-83-2P 478296-84-3P 478296-86-5P
478296-90-1P 478296-91-2P 478296-95-6P 478296-97-8P 478296-98-9P
478297-00-6P 478297-01-7P 478297-03-9P 478297-05-1P 478297-11-9P

478297-13-1P 478297-15-3P 478297-17-5P 478297-18-6P 478297-20-0P
478297-21-1P 478297-22-2P 478297-23-3P 478297-24-4P 478297-25-5P
478297-26-6P 478297-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of GABA analogs as prodrugs)

IT **60142-99-6P 219135-91-8P 219135-98-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of GABA analogs as prodrugs)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435025 CAPLUS
DOCUMENT NUMBER: 135:46446
TITLE: Branched chain amino acid-dependent aminotransferase inhibitors for treatment of diabetic retinopathy
INVENTOR(S): Bryans, Justin Stephen; Hu, Lain-Yen; Hutson, Susan M.; Lanoue, Kathryn Foley; Lieth, Erich; Rafferty, Michael Francis; Ryder, Todd Robert; Su, Ti-Zhi; Welty, Devin Franklin; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Penn State Research Foundation; Wake Forest University
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001042191	A1	20010614	WO 2000-US30769		20001108
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2361647	AA	20010614	CA 2000-2361647		20001108
BR 2000008443	A	20011030	BR 2000-8443		20001108
EP 1157000	A1	20011128	EP 2000-977094		20001108
EP 1157000	B1	20051102			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
EE 200100416	A	20021216	EE 2001-416		20001108
JP 2003516379	T2	20030513	JP 2001-543493		20001108
CN 1626069	A	20050615	CN 2004-10064117		20001108
AT 308510	E	20051115	AT 2000-977094		20001108
ZA 2001006260	A	20021030	ZA 2001-6260		20010730
HR 2001000581	A1	20020831	HR 2001-581		20010803
NO 2001003844	A	20011004	NO 2001-3844		20010807
BG 105875	A	20020531	BG 2001-105875		20010905
HK 1044933	A1	20050603	HK 2002-106385		20020829
PRIORITY APPLN. INFO.:			US 1999-169635P	P	19991208
			US 2000-175399P	P	20000111
			US 2000-230020P	P	20000905
			WO 2000-US30769	W	20001108

OTHER SOURCE(S): MARPAT 135:46446
ED Entered STN: 15 Jun 2001
GI



I

AB Cycloalkylalkanoic acid derivs., e.g., I [R1-R4 = H or alkyl; X = NH, alkylimino, O; R5 = H, alkyl, benzyl, alkanoyl, alkoxyalkanoyl, arylalkyl, alkoxy, cycloalkyl, allyl, alkylcycloalkyl, alkoxy, cycloalkyl, alkylcycloalkyl, tri-substituted haloalkyl (when R1-R4 are each H, R6 ≠ H or Me)] or pharmaceutically acceptable salts, esters, prodrugs, or amides, were prepared Compds. I are inhibitors of the branched chain amino acid-dependent aminotransferase (BCAT) pathway in animals, in particular humans, and thus can be used to treat the retina for diabetic

retinopathy prophylactically or therapeutically. Thus, trans-(1R,3R)-1-(aminomethyl)-3-methylcyclohexylacetic acid hydrochloride, prepared from (R)-3-methylcyclohexanone and Et cyanoacetate by a multistep procedure, showed IC50 = 146 μM in an assay of BCAT.

IC ICM C07C229-28
ICS C07C059-11; C07C059-62; A61K031-19; A61P027-02

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 24

IT **60142-99-6P** 63562-00-5P 66024-98-4P 66025-00-1P
66025-02-3P 66025-09-0P 196608-46-5P 196608-49-8P
223425-81-8P 223425-83-0P 223445-66-7P
223445-67-8P 344459-71-8P 344459-73-0P 344459-77-4P
344459-79-6P 344459-83-2P 344459-85-4P 344459-87-6P 344459-89-8P
344459-91-2P 344459-93-4P 344459-95-6P **344459-99-0P**
344460-02-2P 344460-04-4P 344460-06-6P 344460-08-8P 344460-10-2P
344460-12-4P 344460-16-8P 344460-19-1P 344460-21-5P 344460-23-7P
344460-25-9P 344460-27-1P 344460-29-3P 344460-31-7P 344460-32-8P
344460-34-0P 344460-35-1P 344460-36-2P 344460-38-4P 344460-39-5P
344460-42-0P 344460-44-2P 344460-48-6P 344460-50-0P 344460-53-3P
344460-54-4P 344460-57-7P 344460-58-8P 344460-59-9P 344460-60-2P
344460-61-3P 344460-62-4P 344460-63-5P 344460-64-6P 344460-65-7P
344460-66-8P 344460-67-9P 344460-68-0P 344460-69-1P 344460-70-4P
344460-71-5P 344460-72-6P 344460-73-7P 344460-74-8P 344460-75-9P
344460-76-0P 344460-77-1P 344460-78-2P 344460-79-3P 344571-26-2P
344571-27-3P 344571-28-4P 344574-37-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(branched chain amino acid-dependent aminotransferase inhibitors for treatment of diabetic retinopathy)

IT **60142-99-6P 223425-81-8P 223425-83-0P**
223445-66-7P 223445-67-8P 344459-99-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(branched chain amino acid-dependent aminotransferase inhibitors for treatment of diabetic retinopathy)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 223425-81-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 223425-83-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 223445-66-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 223445-67-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 344459-99-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:68151 CAPLUS
DOCUMENT NUMBER: 132:102843
TITLE: GABA analogs for preventing and treating gastrointestinal damage
INVENTOR(S): Guglietta, Antonio; Taylor, Charles Price, Jr.; Ren, Jiayuan; Watson, W. P.; Rafferty, Michael Francis; Diop, Laurent; Chovet, Maria; Bueno, Lionel; Little, Hilary J.
PATENT ASSIGNEE(S): Jouveinal, Fr.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974351	A2	20000126	EP 1998-401018	19980424
EP 974351	A3	20001213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			EP 1998-401018	19980424

OTHER SOURCE(S): MARPAT 132:102843
ED Entered STN: 28 Jan 2000
AB GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.

IC ICM A61K031-195
CC 1-9 (Pharmacology)
IT 56-12-2D, GABA, analogs 60142-96-3D, esters 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8 63562-03-8D, esters 148553-50-8, Pregabalin 148553-51-9 196608-53-4 **219135-91-8 219135-98-5** 219136-10-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs for preventing and treating gastrointestinal damage)
IT **60142-99-6 60142-99-6D**, esters **219135-91-8 219135-98-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs for preventing and treating gastrointestinal damage)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:297397 CAPLUS
DOCUMENT NUMBER: 130:297006
TITLE: Synthesis of cyclic amino acids and derivatives thereof useful as pharmaceutical agents
INVENTOR(S): Bryans, Justin Stephen; Horwell, David Christopher; Thorpe, Andrew John; Wustrow, David Juergen; Yuen, Po-Wai
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921824	A1	19990506	WO 1998-US19876	19980923
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2303244	AA	19990506	CA 1998-2303244	19980923
CA 2303244	C	20051206		
AU 9896638	A1	19990517	AU 1998-96638	19980923
AU 755800	B2	20021219		
BR 9813284	A	20000822	BR 1998-13284	19980923
EP 1032555	A1	20000906	EP 1998-950649	19980923
EP 1032555	B1	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200001170	T2	20001023	TR 2000-200001170	19980923
JP 2001521020	T2	20011106	JP 2000-517936	19980923
JP 3756761	B2	20060315		
NZ 503651	A	20020927	NZ 1998-503651	19980923
IL 134732	A1	20040328	IL 1998-134732	19980923
CN 1500773	A	20040602	CN 2003-10120932	19980923
AT 323067	E	20060415	AT 1998-950649	19980923
ZA 9809740	A	19990425	ZA 1998-9740	19981026
US 6635673	B1	20031021	US 2000-485382	20000208
NO 2000002118	A	20000426	NO 2000-2118	20000426
HK 1030768	A1	20041217	HK 2001-101728	20010312
US 2003220397	A1	20031127	US 2003-448834	20030530
US 6921835	B2	20050726		
US 2005159487	A1	20050721	US 2005-78961	20050311
JP 2006096758	A2	20060413	JP 2005-319009	20051102

PRIORITY APPLN. INFO.:		
US 1997-63644P	P	19971027
US 1998-97685P	P	19980824
CN 1998-810346	A	19980923
JP 2000-517936	A3	19980923
WO 1998-US19876	W	19980923
US 2000-485382	A1	20000208
US 2003-448834	A3	20030530

OTHER SOURCE(S): MARPAT 130:297006
ED Entered STN: 14 May 1999
GI



I



II

AB The invention is a novel series of cyclic amino acids [(I, II); R = H, alkyl; R1 - R14 independently = H, (branched) alkyl, Ph, CH2Ph, F, Cl, Br, OH, CH2OH, NH2, CH2NH2, CF3, CO2h, CO2R15; CH2CO2R15, OR15; R15 = (branched) alkyl, Ph, CH2Ph, and R1-R8 are not simultaneously H] which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuro-pathol. disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compds. and novel intermediates useful in the preparation of the final compds. are included. Thus, trans-3,4-dimethyl-cyclopentanone was reacted with triethylphosphonoacetate and NaH to give trans-(3,4-dimethyl-cyclopentylidene)acetic acid Et ester; this unsatd. ester was then reacted with H3CNO2 to give trans-(3,4-dimethyl-1-nitro-methyl-cyclopentyl)acetic acid Et ester (III). III was hydrogenated to give a spiro-lactam, which was then ring-opened to give I (R = H, R1-R3, R6-R8 = H, R4,R5 = trans-Me's) as the HCl salt. In in vivo tests, III had IC50 of 0.034 μM in carrageenan-induced thermal hyperalgesia tests using rats; in anticonvulsant efficacy tests using DBA/2 audiogenic mice, III had 100% efficiency at 1 h post-dose at 30 mg/kg.

IC ICM C07C229-28
ICS C07C229-34; A61K031-195

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 24, 63

IT 223425-86-3 **223425-88-5 223425-89-6**
223425-90-9 223425-91-0 223425-92-1
223425-93-2 223425-94-3 223425-95-4
223425-97-6 223425-98-7 223425-99-8
223426-00-4 223426-01-5 223426-02-6
223426-03-7 223426-04-8 223426-05-9
223426-07-1 223426-08-2 223426-09-3
223426-10-6 223426-11-7 223426-12-8
223426-13-9 223426-14-0 223426-16-2
223426-17-3 223426-18-4 223426-19-5
223426-20-8 223426-21-9 223426-22-0
223426-23-1 223426-24-2 223426-25-3
223426-26-4 223426-27-5 223426-28-6
223426-29-7 223426-30-0 223426-31-1
223426-32-2 223426-33-3 223426-34-4
223426-35-5 223426-36-6 223426-37-7
223426-38-8 223426-39-9 223426-40-2
223426-42-4 223426-43-5 223426-44-6
223426-45-7 223426-46-8 223426-47-9
223426-48-0 223426-49-1 223426-50-4

223426-51-5 223426-52-6 223426-54-8
223426-55-9 223426-56-0 223426-57-1
223426-58-2 223426-60-6 223426-61-7
223426-62-8 223426-63-9 223426-64-0
223426-65-1 223426-66-2 223426-67-3
223426-68-4 223426-70-8 223426-71-9
223426-72-0 223426-74-2 223426-76-4
223426-77-5 223426-79-7 223426-80-0
223426-81-1 223426-82-2 223426-83-3
223426-84-4 223426-85-5 223426-86-6
223426-87-7 223426-88-8 223426-89-9
223426-90-2 223426-91-3 223426-92-4
223426-93-5 223426-94-6 223426-95-7
223426-96-8 223426-97-9 223426-98-0
223426-99-1 223427-00-7 223427-01-8
223427-02-9 223427-03-0 223427-04-1
223427-05-2 223427-06-3 223427-07-4
223427-08-5 223427-09-6 223427-10-9
223427-11-0 223427-12-1 223427-13-2
223427-15-4 223427-16-5 223427-17-6
223427-18-7 223427-20-1 223427-21-2
223427-22-3 223427-23-4 223427-24-5
223427-25-6 223427-26-7 223427-28-9
223427-30-3 223427-31-4 223427-32-5
223427-33-6 223427-34-7 223427-35-8
223427-37-0 223427-38-1 223427-39-2
223427-40-5 223427-41-6 223427-42-7
223427-43-8 223427-45-0 223427-46-1
223427-47-2 223427-48-3 223427-49-4
223427-50-7 223427-51-8 223427-53-0
223427-54-1 223427-55-2 223427-56-3
223427-57-4 223427-58-5 223427-60-9
223427-61-0 223427-62-1 223427-63-2
223427-64-3 223427-65-4 223427-66-5
223427-67-6 223427-68-7 223427-69-8
223427-70-1 223427-71-2 223427-72-3
223427-73-4 223427-74-5 223427-76-7
223427-77-8 223427-78-9 223427-79-0
223427-80-3 223427-81-4 223427-82-5
223427-83-6 223427-84-7 223427-86-9
223427-87-0 223427-88-1 223427-89-2
223427-90-5 223427-91-6 223427-92-7
223427-93-8 223427-94-9 223427-95-0
223427-97-2 223427-98-3 223427-99-4
223428-00-0 223428-01-1 223428-02-2
223428-03-3 223428-04-4 223428-05-5
223428-06-6 223428-07-7 223428-08-8
223428-09-9 223428-10-2 223428-12-4
223428-13-5 223428-14-6 223428-15-7
223428-16-8 223428-17-9 223428-18-0
223428-19-1 223428-20-4 223428-21-5
223428-22-6 223428-58-8 223445-09-8
223445-69-0 223445-70-3 223445-71-4
223445-72-5 223445-73-6 223445-74-7
223445-75-8 223445-76-9 223445-77-0
223445-78-1 223445-79-2 223445-80-5
223445-81-6 223445-82-7 223445-83-8
223445-84-9 223445-85-0 223445-86-1
223445-87-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclic amino acids as pharmaceutical agents)

IT 27741-65-7P 223425-55-6P 223425-58-9P 223425-60-3P 223425-65-8P
223425-66-9P 223425-67-0P 223425-68-1P 223425-69-2P 223425-70-5P
223425-71-6P 223425-73-8P **223425-75-0P** 223425-77-2P
223425-78-3P 223425-79-4P 223425-80-7P 223445-59-8P 223445-60-1P
223445-61-2P 223445-62-3P 223445-63-4P 223445-64-5P
223445-65-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of in the synthesis of cyclic amino acids and derivs. thereof useful as pharmaceutical agents)

IT **223425-81-8P 223425-82-9P 223425-83-0P**
223425-84-1P **223425-85-2P 223445-66-7P**
223445-67-8P 223445-68-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amino acids as pharmaceutical agents)

IT **223425-88-5 223425-89-6 223425-90-9**
223425-91-0 223425-92-1 223425-93-2
223425-94-3 223425-95-4 223425-97-6
223425-98-7 223425-99-8 223426-00-4
223426-01-5 223426-02-6 223426-03-7
223426-04-8 223426-05-9 223426-07-1
223426-08-2 223426-09-3 223426-10-6
223426-11-7 223426-12-8 223426-13-9
223426-14-0 223426-16-2 223426-17-3
223426-18-4 223426-19-5 223426-20-8
223426-21-9 223426-22-0 223426-23-1
223426-24-2 223426-25-3 223426-26-4
223426-27-5 223426-28-6 223426-29-7
223426-30-0 223426-31-1 223426-32-2
223426-33-3 223426-34-4 223426-35-5
223426-36-6 223426-37-7 223426-38-8
223426-39-9 223426-40-2 223426-42-4
223426-43-5 223426-44-6 223426-45-7
223426-46-8 223426-47-9 223426-48-0
223426-49-1 223426-50-4 223426-51-5
223426-52-6 223426-54-8 223426-55-9
223426-56-0 223426-57-1 223426-58-2
223426-60-6 223426-61-7 223426-62-8
223426-63-9 223426-64-0 223426-65-1
223426-66-2 223426-67-3 223426-68-4
223426-70-8 223426-71-9 223426-72-0
223426-74-2 223426-76-4 223426-77-5
223426-79-7 223426-80-0 223426-81-1
223426-82-2 223426-83-3 223426-84-4
223426-85-5 223426-86-6 223426-87-7
223426-88-8 223426-89-9 223426-90-2
223426-91-3 223426-92-4 223426-93-5
223426-94-6 223426-95-7 223426-96-8
223426-97-9 223426-98-0 223426-99-1
223427-00-7 223427-01-8 223427-02-9
223427-03-0 223427-04-1 223427-05-2
223427-06-3 223427-07-4 223427-08-5
223427-09-6 223427-10-9 223427-11-0
223427-12-1 223427-13-2 223427-15-4
223427-16-5 223427-17-6 223427-18-7
223427-20-1 223427-21-2 223427-22-3
223427-23-4 223427-24-5 223427-25-6
223427-26-7 223427-28-9 223427-30-3

223427-31-4 223427-32-5 223427-33-6
223427-34-7 223427-35-8 223427-37-0
223427-38-1 223427-39-2 223427-40-5
223427-41-6 223427-42-7 223427-43-8
223427-45-0 223427-46-1 223427-47-2
223427-48-3 223427-49-4 223427-50-7
223427-51-8 223427-53-0 223427-54-1
223427-55-2 223427-56-3 223427-57-4
223427-58-5 223427-60-9 223427-61-0
223427-62-1 223427-63-2 223427-64-3
223427-65-4 223427-66-5 223427-67-6
223427-68-7 223427-69-8 223427-70-1
223427-71-2 223427-72-3 223427-73-4
223427-74-5 223427-76-7 223427-77-8
223427-78-9 223427-79-0 223427-80-3
223427-81-4 223427-82-5 223427-83-6
223427-84-7 223427-86-9 223427-87-0
223427-88-1 223427-89-2 223427-90-5
223427-91-6 223427-92-7 223427-93-8
223427-94-9 223427-95-0 223427-97-2
223427-98-3 223427-99-4 223428-00-0
223428-01-1 223428-02-2 223428-03-3
223428-04-4 223428-05-5 223428-06-6
223428-07-7 223428-08-8 223428-09-9
223428-10-2 223428-12-4 223428-13-5
223428-14-6 223428-15-7 223428-16-8
223428-17-9 223428-18-0 223428-19-1
223428-20-4 223428-21-5 223428-22-6
223428-58-8 223445-09-8 223445-69-0
223445-70-3 223445-71-4 223445-72-5
223445-73-6 223445-74-7 223445-75-8
223445-76-9 223445-77-0 223445-78-1
223445-79-2 223445-80-5 223445-81-6
223445-82-7 223445-83-8 223445-84-9
223445-85-0 223445-86-1 223445-87-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic amino acids as pharmaceutical agents)

RN 223425-88-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 223425-89-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223425-90-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1-methylethyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223425-91-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1S,3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-92-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1R,3S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-93-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-94-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-95-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-97-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-98-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223425-99-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-00-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-01-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-02-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-03-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-04-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1,1-dimethylethyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-05-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1S,3S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-07-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1R,3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-08-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-09-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-10-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-11-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-12-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, (1S,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-13-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, (1S,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-14-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-16-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-17-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-18-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-19-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, (1R,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-20-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, (1R,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-21-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-22-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-23-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-dimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-24-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-diethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-25-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3,4,4-tetramethyl- (9CI) (CA INDEX NAME)



RN 223426-26-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3,4,4-tetraethyl- (9CI) (CA INDEX NAME)



RN 223426-27-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1R,3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-28-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1S,3S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-29-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-30-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-31-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-32-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-33-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-34-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-35-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-36-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-37-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-38-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-39-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1R,3S,4R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-40-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1S,3R,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-42-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-,
(1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-43-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-,
(1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-44-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-45-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-46-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-47-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-48-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-49-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-50-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-51-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-52-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-54-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, (1S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-55-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-56-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-57-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-dimethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-58-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-diethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-60-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-61-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-62-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-63-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-64-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-65-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-66-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-67-3 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-68-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-70-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-71-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-72-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-74-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-76-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-(1-methylethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-77-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-79-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-80-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-81-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-82-2 CAPLUS

CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-(1-methylethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-83-3 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-84-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-85-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-methyl-3-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-86-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-(1-methylethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-87-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-ethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-88-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-89-9 CAPLUS

CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-90-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-(1-methylethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-91-3 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-ethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-92-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-93-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-ethyl-3-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-94-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-(1-methylethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-95-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-3-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-96-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-3-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-97-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-98-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223426-99-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-(1-methylethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223427-00-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-3-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223427-01-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223427-02-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223427-03-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 223427-04-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-diethyl- (9CI) (CA INDEX NAME)



RN 223427-05-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 223427-06-3 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 223427-07-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-diphenyl- (9CI) (CA INDEX NAME)



RN 223427-08-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3,3-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 223427-09-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,2,4,4-tetramethyl- (9CI) (CA INDEX NAME)



RN 223427-10-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,2,3,3,4,4-hexamethyl- (9CI) (CA INDEX NAME)



RN 223427-11-0 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,2-dimethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-12-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-13-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2-methyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-15-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-16-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1α,2β,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223427-17-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-18-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2-methyl-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-20-1 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-21-2 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-22-3 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2-methyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-23-4 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-24-5 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2-ethyl-4-methyl-, (1R,2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-25-6 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-26-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2-methyl-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-28-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-30-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diphenyl-, (1α,3α,4β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-31-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(phenylmethyl)-, (1α,3α,4β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-32-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1S,3S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-33-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1R,3S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-34-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1R,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-35-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-methyl-, (1S,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-37-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-38-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-39-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-40-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(1-methylethyl)-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-41-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-42-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-43-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-methyl-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-45-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-46-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1R,3S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-47-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1R,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-48-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-phenyl-, (1S,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-49-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-50-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-51-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-53-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-4-(phenylmethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-54-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-55-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-56-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-57-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(1-methylethyl)-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-58-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-60-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-61-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-62-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-ethyl-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-63-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-phenyl-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-64-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-phenyl-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-65-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-phenyl-, (1R,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-66-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-phenyl-, (1S,3R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-67-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(phenylmethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-68-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(phenylmethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-69-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(phenylmethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-70-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-4-(phenylmethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-71-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-72-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-73-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-74-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(1-methylethyl)-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-76-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-phenyl-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-77-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-phenyl-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-78-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-phenyl-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-79-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-phenyl-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-80-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-(phenylmethyl)-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-81-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-(phenylmethyl)-, (1R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-82-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-(phenylmethyl)-, (1R,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-83-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1-methylethyl)-4-(phenylmethyl)-, (1S,3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-84-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-phenyl-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-86-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-phenyl-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-87-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-phenyl-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-88-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-phenyl-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-89-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(phenylmethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-90-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(phenylmethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-91-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(phenylmethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-92-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-4-(phenylmethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-93-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-4-(phenylmethyl)-, (1S,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-94-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-4-(phenylmethyl)-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-95-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-4-(phenylmethyl)-, (1R,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-97-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-phenyl-4-(phenylmethyl)-, (1S,3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-98-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2-methyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223427-99-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2-methyl-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-00-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2-methyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-01-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2-methyl-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-02-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,2-dimethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-03-3 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-04-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 223428-05-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,5-dimethyl-, (1α,2α,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223428-06-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-07-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-08-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-09-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1R,2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-10-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-12-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-13-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-14-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,3-dimethyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-15-7 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1R,2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-16-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1S,2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-17-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1R,2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-18-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1S,2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-19-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1R,2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-20-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1S,2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-21-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1R,2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-22-6 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1S,2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223428-58-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-3-(1,1-dimethylethyl)-3-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-09-8 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (1α,2α,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-69-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-70-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (1α,3α,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-71-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diethyl-, (1α,3α,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-72-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1-methylethyl)-, (1α,3α,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-73-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1,1-dimethylethyl)-, (1α,3α,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-74-7 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-2,4-dimethyl-, (2R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 223445-75-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-76-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-77-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diethyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-78-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diethyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-79-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1-methylethyl)-, (3S,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-80-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1-methylethyl)-, (3R,4R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-81-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1,1-dimethylethyl)-,
(3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-82-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(1,1-dimethylethyl)-,
(3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-83-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-diphenyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-84-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-bis(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-85-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,5-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-86-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,5-dimethyl-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-87-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-2,5-dimethyl-, (1α,2β,5β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **223425-75-0P 223445-65-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of in the synthesis of cyclic amino acids and derivs. thereof useful as pharmaceutical agents)
RN 223425-75-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, ethyl ester, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223445-65-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, ethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **223425-81-8P 223425-82-9P 223425-83-0P 223425-85-2P 223445-66-7P 223445-67-8P 223445-68-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amino acids as pharmaceutical agents)

RN 223425-81-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 223425-82-9 CAPLUS
CN Cyclobutaneacetic acid, 1-(aminomethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223425-83-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 223425-85-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,3-dimethyl-, hydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 223445-66-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 223445-67-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 223445-68-9 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl-, hydrochloride, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:141204 CAPLUS
DOCUMENT NUMBER: 130:191891
TITLE: GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome
INVENTOR(S): Guglietta, Antonio; Taylor, Charles, Price, Jr.; Ren, Jiayuan; Watson, W. P.; Rafferty, Michael Francis; Diop, Laurent; Chovet, Maria; Bueno, Lionel; Little, Hilary J.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; The University of Oklahoma
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9908671	A1	19990225	WO 1998-US17082	19980818
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2297163	AA	19990225	CA 1998-2297163	19980818
CA 2297163	C	20011120		
AU 9892930	A1	19990308	AU 1998-92930	19980818
EP 1009399	A1	20000621	EP 1998-945758	19980818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9812133	A	20000718	BR 1998-12133	19980818
JP 2001515033	T2	20010918	JP 2000-509411	19980818
NZ 502729	A	20021025	NZ 1998-502729	19980818
TW 570794	B	20040111	TW 1998-87113592	19980818
IL 134164	A1	20050517	IL 1998-134164	19980818
ZA 9807493	A	19990707	ZA 1998-7493	19980819
US 6127418	A	20001003	US 1999-284710	19990419
MX 200001093	A	20001020	MX 2000-1093	20000131
NO 2000000786	A	20000217	NO 2000-786	20000217
US 6242488	B1	20010605	US 2000-567191	20000509

US 2001014698	A1	20010816	US 2001-804742	20010313
US 6426368	B2	20020730		

PRIORITY APPLN. INFO.:

US 1997-56753P	P	19970820
US 1998-74794P	P	19980216
US 1998-82936P	P	19980424
WO 1998-US17082	W	19980818
US 1999-284710	A3	19990419
US 2000-567191	A3	20000509

OTHER SOURCE(S): MARPAT 130:191891
ED Entered STN: 05 Mar 1999
AB GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.
IC ICM A61K031-195
CC 1-9 (Pharmacology)
Section cross-reference(s): 63
IT 56-12-2D, GABA, analogs 34597-40-5, Fenoprofen calcium 60142-96-3 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8 63562-03-8D, esters 148553-50-8, Pregabalin 148553-51-9 196608-53-4 **219135-91-8 219135-98-5** 219136-10-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome)
IT **60142-99-6 60142-99-6D**, esters **219135-91-8 219135-98-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:141203 CAPLUS
DOCUMENT NUMBER: 130:191890
TITLE: GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome
INVENTOR(S): Guglietta, Antonio; Taylor, Charles Price, Jr.; Ren, Jiayuan; Watson, W. P.; Rafferty, Michael Francis; Diop, Laurent; Chovet, Maria; Bueno, Lionel; Little, Hilary J.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; The University of Oklahoma; Taylor, Charles Price, Jr.; et al.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9908670	A1	19990225	WO 1998-US15694		19980729
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9886685	A1	19990308	AU 1998-86685		19980729
TW 570794	B	20040111	TW 1998-87113592		19980818
ZA 9807493	A	19990707	ZA 1998-7493		19980819
US 6242488	B1	20010605	US 2000-567191		20000509
PRIORITY APPLN. INFO.:			US 1997-56753P	P	19970820
			US 1998-74794P	P	19980216
			US 1998-82936P	P	19980424
			WO 1998-US15694	W	19980424
			US 1999-284710	A3	19990419

OTHER SOURCE(S): MARPAT 130:191890
ED Entered STN: 05 Mar 1999
AB GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.
IC ICM A61K031-195
CC 1-9 (Pharmacology)
Section cross-reference(s): 63
IT 56-12-2D, GABA, analogs 34597-40-5, Fenoprofen calcium 60142-96-3 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8 63562-03-8D, esters 148553-50-8, Pregabalin 148553-51-9 196608-53-4 **219135-91-8 219135-98-5** 219136-10-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome)
IT **60142-99-6 60142-99-6D**, esters **219135-91-8 219135-98-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:27708 CAPLUS
DOCUMENT NUMBER: 130:90504
TITLE: Use of GABA analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases
INVENTOR(S): Schrier, Denis; Taylor, Charles Price, Jr.; Westlund-High, Karin Nanette
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Board of Regents of the University of Texas System
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858641	A1	19981230	WO 1998-US13107	19980624
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294607	AA	19981230	CA 1998-2294607	19980624
AU 9883758	A1	19990104	AU 1998-83758	19980624
AU 735675	B2	20010712		
ZA 9805517	A	19990120	ZA 1998-5517	19980624
EP 994704	A1	20000426	EP 1998-934170	19980624
EP 994704	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9812265	A	20000718	BR 1998-12265	19980624
JP 2002506449	T2	20020226	JP 1999-505021	19980624
NZ 501626	A	20020328	NZ 1998-501626	19980624
AT 297722	E	20050715	AT 1998-934170	19980624
ES 2244070	T3	20051201	ES 1998-934170	19980624
US 6329429	B1	20011211	US 1999-403867	19991025
MX 9909996	A	20000331	MX 1999-9996	19991029
NO 9906468	A	20000221	NO 1999-6468	19991223
US 2002032235	A1	20020314	US 2001-924656	20010808
US 6887902	B2	20050503		

PRIORITY APPLN. INFO.:			
	US 1997-50736P	P	19970625
	US 1998-84183P	P	19980504
	WO 1998-US13107	W	19980624

US 1999-403867 A3 19991025

OTHER SOURCE(S): MARPAT 130:90504
ED Entered STN: 14 Jan 1999
AB GABA analogs, e.g. gabapentin and pregabalin, are useful for the prevention and treatment of inflammatory diseases.
IC ICM A61K031-195
CC 1-7 (Pharmacology)
IT 56-12-2D, GABA, analogs 60142-96-3, Gabapentin 148553-50-8, Pregabalin 148553-51-9 196608-53-4 **219135-91-8 219135-98-5** 219136-10-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin or other GABA analog for treatment of inflammatory disease)
IT **219135-91-8 219135-98-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin or other GABA analog for treatment of inflammatory disease)
RN 219135-91-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 219135-98-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

THE ESTIMATED COST FOR THIS REQUEST IS 97.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L15 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:364647 CAPLUS
DOCUMENT NUMBER: 144:350975
TITLE: Method for the stereoselective synthesis of cyclic amino acids
INVENTOR(S): Bryans, Justin Stephen; Blakemore, David Clive; Williams, Sophie Caroline
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S. Pat. Appl. Publ., 72 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006084825	A1	20060420	US 2004-968430	20041019

PRIORITY APPLN. INFO.: US 2004-968430 20041019
ED Entered STN: 21 Apr 2006
GI



I

AB The invention relates to the synthesis of stereoisomeric 1-(aminomethyl)cyclopentylacetic acid derivs. I (R = C1-10 alkyl or C3-C10 cycloalkyl) or their pharmaceutically-acceptable salts, which are useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathol. disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammation especially arthritis, sleep disorders, premenstrual syndrome, and hot flashes. Compds. I are 3-substituted cyclopentyl-based analogs of gabapentin. Thus, (1S,3R)-1-(aminomethyl)-3-methylcyclopentylacetic acid hydrochloride was prepared by a multistep procedure starting with the condensation of (R)-(+)-3-methylcyclopentanone with Et cyanoacetate.

INCL 562504000
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
IT **223425-88-5P 223426-50-4P 342652-27-1P 342652-57-7P 342652-58-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective synthesis of cyclic amino acids)
IT **223425-88-5P 223426-50-4P 342652-27-1P 342652-57-7P 342652-58-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective synthesis of cyclic amino acids)
RN 223425-88-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 223426-50-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342652-27-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342652-57-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342652-58-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, hydrochloride, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L15 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:591003 CAPLUS
DOCUMENT NUMBER: 139:128044
TITLE: Pharmaceutical composition and method using a GABA analog, an NMDA antagonist, and an optional additional drug for treating disorders of the central nervous system
INVENTOR(S): Galer, Bradley S.; Schlagheck, Thomas G.
PATENT ASSIGNEE(S): Endo Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061656	A1	20030731	WO 2003-US794	20030110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473536	AA	20030731	CA 2003-2473536	20030110
EP 1471909	A1	20041103	EP 2003-731905	20030110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005518411	T2	20050623	JP 2003-561600	20030110
CN 1642547	A	20050720	CN 2003-806180	20030110
PRIORITY APPLN. INFO.:			US 2002-349773P P	20020116
			WO 2003-US794 W	20030110

OTHER SOURCE(S): MARPAT 139:128044
ED Entered STN: 01 Aug 2003
AB Disorders of the central nervous system (CNS) are treated by the administration of a GABA analog (e.g. gabapentin or pregabalin), an NMDA receptor antagonist (e.g. dextromethorphan or d-methadone), and, optionally, another pharmacol. active substance, e.g., one which is effective for the treatment of a CNS disorder.

IC ICM A61K031-44
ICS A61K031-195
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine, biological studies 52-86-8, , Haloperidol 56-12-2D, GABA, analogs 69-23-8, Fluphenazine 72-69-5, Nortriptyline 113-45-1, Methyl phenidate 125-71-3, Dextromethorphan 125-73-5, Dextrorphan 303-49-1, Clomipramine 321-64-2, , Tacrine 768-94-5, Amantadine 1622-61-3, Clonazepam 1668-19-5, Doxepin 1744-22-5, Riluzole 2062-78-4, , Pimozide 4205-90-7, Clonidine 5653-80-5 12794-10-4D, Benzodiazepine, derivs. 14611-51-9, Selegiline 19794-93-5, Trazodone 19982-08-2, Memantine 25614-03-3, Bromocriptine 31677-93-7, , Bupropion hydrochloride 36505-84-7, , Buspirone 54910-89-3, Fluoxetine 57308-51-7, Carbidopa-levodopa mixture 60142-96-3 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 61869-08-7, Paroxetine 63562-03-8 63562-03-8D, esters 79617-96-2, Sertraline 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 92623-85-3, , Milnacipran 93413-69-5, Venlafaxine 116539-59-4, Duloxetine 120014-06-4, Donepezil 148553-50-8, Pregabalin 569296-24-8 569296-25-9 569296-26-0 569296-27-1 569296-28-2 569296-29-3 569296-30-6 569296-31-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog, NMDA antagonist, and optional addnl. drug for treating CNS disorders)
IT **60142-99-6 60142-99-6D**, esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog, NMDA antagonist, and optional addnl. drug for treating CNS disorders)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435024 CAPLUS
DOCUMENT NUMBER: 135:19914
TITLE: Method for the stereoselective synthesis of cyclic amino acids
INVENTOR(S): Bryans, Justin Stephen; Blakemore, David Clive; Williams, Sophie Caroline

PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042190	A1	20010614	WO 2000-US32570	20001130
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2392761	AA	20010614	CA 2000-2392761	20001130
BR 2000016201	A	20020813	BR 2000-16201	20001130
EP 1237847	A1	20020911	EP 2000-980881	20001130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003516378	T2	20030513	JP 2001-543492	20001130
CN 1607201	A	20050420	CN 2004-10062843	20001130
ZA 2002003628	A	20030807	ZA 2002-3628	20020507
US 2003069438	A1	20030410	US 2002-149160	20020606
US 6864390	B2	20050308		

PRIORITY APPLN. INFO.: US 1999-169602P P 19991208
WO 2000-US32570 W 20001130

OTHER SOURCE(S): CASREACT 135:19914; MARPAT 135:19914
ED Entered STN: 15 Jun 2001
GI



I

AB Stereoisomeric 1-(aminomethyl)cyclopentylacetic acid derivs. I (R = C1-10 alkyl or C3-C10 cycloalkyl) or their pharmaceutically acceptable salts were prepared for treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathol. disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammation especially arthritis, sleep disorders, premenstrual syndrome, and hot flashes. Compds. I are 3-substituted cyclopentyl-based analogs of gabapentin. Thus, (1S,3R)-1-(aminomethyl)-3-methylcyclopentylacetic acid hydrochloride was prepared by a multistep procedure starting with the condensation of (R)-(+)-3-methylcyclopentanone with Et cyanoacetate.

IC ICM C07C227-32
ICS C07C229-28; C07C057-46; C07C255-31; C07C255-41; C07C265-08; C07C271-12; C07C069-616
CC 34-2 (Amino Acids, Peptides, and Proteins)

IT **223425-88-5P 223426-17-3P 223426-18-4P**
223426-50-4P 223426-51-5P 342652-27-1P
342652-51-1P 342652-52-2P 342652-54-4P
342652-56-6P 342652-57-7P 342652-58-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective synthesis of cyclic amino acids)

IT **223425-88-5P 223426-17-3P 223426-18-4P**
223426-50-4P 223426-51-5P 342652-27-1P
342652-51-1P 342652-52-2P 342652-54-4P
342652-56-6P 342652-57-7P 342652-58-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective synthesis of cyclic amino acids)

RN 223425-88-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 223426-17-3 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-18-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-50-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223426-51-5 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342652-27-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-methyl-, hydrochloride, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342652-51-1 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, hydrochloride, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342652-52-2 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342652-54-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, hydrochloride, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342652-56-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-ethyl-, hydrochloride, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342652-57-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342652-58-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-3-propyl-, hydrochloride, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:814298 CAPLUS
DOCUMENT NUMBER: 133:344633
TITLE: Modulation of substance P by GABA analogs, and therapeutic methods
INVENTOR(S): Magistro, Philip John, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067742	A2	20001116	WO 2000-US6199	20000310
WO 2000067742	A3	20010816		

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-132614P P 19990505

OTHER SOURCE(S): MARPAT 133:344633

ED Entered STN: 21 Nov 2000

AB Modulation of substance P by GABA analogs is disclosed. Preferred GABA analog compds. include gabapentin and pregabalin. Methods of the invention include the modulation of substance P, as well as methods for preventing or treating conditions associated with substance P, by administering to an animal an effective amount of one or more GABA analog compds. Conditions associated with substance P include headaches and migraine, neurogenic inflammation, emesis, nausea and vomiting, cough and bronchitis, obesity, allergy, asthma, hemorrhoids and anal fissures, ulcer, fever, infertility and periodontal disease.

IC ICM A61K031-00

CC 1-11 (Pharmacology)
Section cross-reference(s): 63

IT 56-12-2D, GABA, analogs 60142-96-3 60142-96-3D, esters and isomers **60142-99-6 60142-99-6D**, esters and isomers 63562-03-8 63562-03-8D, esters and isomers 148553-50-8, Pregabalin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog substance P modulators, and therapeutic use)

IT **60142-99-6 60142-99-6D**, esters and isomers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog substance P modulators, and therapeutic use)

RN 60142-99-6 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:53372 CAPLUS
DOCUMENT NUMBER: 132:88190
TITLE: The treatment of renal colic-associated pain with GABA analogs
INVENTOR(S): Angello, James T.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002547	A2	20000120	WO 1999-US15387	19990708
WO 2000002547	A3	20000504		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332931	AA	20000120	CA 1999-2332931	19990708
AU 9950922	A1	20000201	AU 1999-50922	19990708
AU 766708	B2	20031023		
BR 9911925	A	20010327	BR 1999-11925	19990708
EP 1094804	A2	20010502	EP 1999-935443	19990708
EP 1094804	B1	20051005		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 509230	A	20030829	NZ 1999-509230	19990708
AT 305778	E	20051015	AT 1999-935443	19990708
ES 2249905	T3	20060401	ES 1999-935443	19990708
ZA 2000007172	A	20020304	ZA 2000-7172	20001204
US 6680343	B1	20040120	US 2000-720007	20001219
NO 2001000115	A	20010108	NO 2001-115	20010108
PRIORITY APPLN. INFO.:			US 1998-92167P P	19980709
			WO 1999-US15387 W	19990708

OTHER SOURCE(S): MARPAT 132:88190
ED Entered STN: 23 Jan 2000
AB A method is provided for using certain analogs of glutamic acid and γ-aminobutyric acid to relieve the pain associated with renal colic.
IC ICM A61K031-00
CC 1-11 (Pharmacology)
IT 56-12-2D, GABA, analogs 60142-96-3, Gabapentin 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8D, esters 63562-03-8D, esters 148553-50-8, Pregabalin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA/glutamate analogs for treatment of renal colic-associated pain)
IT **60142-99-6 60142-99-6D**, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA/glutamate analogs for treatment of renal colic-associated pain)
RN 60142-99-6 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:53370 CAPLUS
DOCUMENT NUMBER: 132:88189
TITLE: Method for the treatment of insomnia using a GABA or glutamic acid analog
INVENTOR(S): Magnus-Miller, Leslie; Segal, Catherine A.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002546	A2	20000120	WO 1999-US15058	19990701
WO 2000002546	A3	20000615		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2333024	AA	20000120	CA 1999-2333024	19990701
CA 2333024	C	20020326		
AU 9949673	A1	20000201	AU 1999-49673	19990701
AU 765038	B2	20030904		
BR 9911887	A	20010327	BR 1999-11887	19990701
EP 1094803	A2	20010502	EP 1999-933667	19990701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002520277	T2	20020709	JP 2000-558806	19990701
NZ 509231	A	20030829	NZ 1999-509231	19990701
ZA 2000007174	A	20020304	ZA 2000-7174	20001204
NO 2001000117	A	20010108	NO 2001-117	20010108
US 6306910	B1	20011023	US 2001-743370	20010109
US 2002004528	A1	20020110	US 2001-921682	20010803
PRIORITY APPLN. INFO.:			US 1998-92166P P	19980709

WO 1999-US15058 W 19990701
US 2001-743370 A3 20010109

OTHER SOURCE(S): MARPAT 132:88189
ED Entered STN: 23 Jan 2000
AB A method is disclosed for using certain analogs of glutamic acid and γ-aminobutyric acid to treat insomnia.
IC ICM A61K031-00
CC 1-11 (Pharmacology)
IT 56-12-2D, GABA, analogs 60142-96-3, Gabapentin 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8D, esters 63562-03-8D, esters 148553-50-8, Pregabalin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog for insomnia treatment)
IT **60142-99-6 60142-99-6D**, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog for insomnia treatment)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:53369 CAPLUS
DOCUMENT NUMBER: 132:88188
TITLE: Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
INVENTOR(S): Magnus, Leslie; Segal, Catherine A.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002545	A2	20000120	WO 1999-US13946	19990618
WO 2000002545	A3	20000413		

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU,

ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2332927	AA	20000120	CA 1999-2332927		19990618
AU 9945799	A1	20000201	AU 1999-45799		19990618
AU 758103	B2	20030313			
EP 1093365	A2	20010425	EP 1999-928815		19990618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9911943	A	20010529	BR 1999-11943		19990618
NZ 508491	A	20030926	NZ 1999-508491		19990618
ZA 2000007170	A	20020304	ZA 2000-7170		20001204
NO 2001000118	A	20010108	NO 2001-118		20010108
US 2004002543	A1	20040101	US 2003-610386		20030630
PRIORITY APPLN. INFO.:			US 1998-92146P	P	19980709
			WO 1999-US13946	W	19990618
			US 2001-743433	B1	20010216

OTHER SOURCE(S): MARPAT 132:88188
ED Entered STN: 23 Jan 2000
AB The invention is composition and method for treating sinus headache or sinus pain including analogs of glutamic acid and γ-aminobutyric acid in combination with a decongestant.
IC ICM A61K031-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 56-12-2D, GABA, analogs 59-42-7, Phenylephrine 90-82-4, Pseudoephedrine 299-42-3, Ephedrine 60142-96-3, Gabapentin 60142-96-3D, esters **60142-99-6 60142-99-6D**, esters 63562-03-8 63562-03-8D, esters 148553-50-8, Pregabalin 254990-38-0, Ma huong
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog and decongestant to relieve sinus headache pain)
IT **60142-99-6 60142-99-6D**, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA analog and decongestant to relieve sinus headache pain)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:487208 CAPLUS
DOCUMENT NUMBER: 131:111443
TITLE: Gabapentin and its derivatives for the treatment of muscular and skeletal pain
INVENTOR(S): Magnus-Miller, Leslie; Segal, Catherine A.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937296	A1	19990729	WO 1999-US1290	19990122
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309354	AA	19990729	CA 1999-2309354	19990122
AU 9924630	A1	19990809	AU 1999-24630	19990122
EP 1047414	A1	20001102	EP 1999-904178	19990122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1998-72397P P 19980123
WO 1999-US1290 W 19990122

OTHER SOURCE(S): MARPAT 131:111443
ED Entered STN: 06 Aug 1999
AB The invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid to relieve muscular/skeletal back pain.
IC ICM A61K031-195
CC 1-11 (Pharmacology)
IT 60142-96-3 60142-96-3D, esters **60142-99-6 60142-99-6D**
, esters 63562-03-8 63562-03-8D, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin and its derivs. for the treatment of muscular and skeletal pain)
IT **60142-99-6 60142-99-6D**, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin and its derivs. for the treatment of muscular and skeletal pain)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:136813 CAPLUS
DOCUMENT NUMBER: 130:205144
TITLE: Methods using gabapentin and related amino acids for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
INVENTOR(S): Akunne, Hyacinth Chi; Green, Alysia Latrese; Corbin, Ann Elizabeth; Heffner, Thomas Gary; Dooley, David James
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9908667	A2	19990225	WO 1998-US16847		19980813
WO 9908667	A3	19990506			
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9890191	A1	19990308	AU 1998-90191		19980813
ZA 9807439	A	19990226	ZA 1998-7439		19980818
US 6194459	B1	20010227	US 2000-485022		20000202
US 6566400	B1	20030520	US 2000-650313		20000829
PRIORITY APPLN. INFO.:			US 1997-56189P	P	19970819
			WO 1998-US16847	W	19980813
			US 2000-485022	A3	20000202

OTHER SOURCE(S): MARPAT 130:205144
ED Entered STN: 03 Mar 1999
AB The invention is novel uses of known cyclic amino acids. Such compds. as

gabapentin and pregabalin are used for treating physiol. conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants and other addictive drugs/substances. Physiol. conditions include stimulant-induced toxicities.

IC ICM A61K031-00

CC 1-11 (Pharmacology)
Section cross-reference(s): 63

IT 60142-96-3 60142-96-3D, esters **60142-99-6 60142-99-6D**
, esters 63562-03-8 63562-03-8D, esters 148553-50-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin and related amino acids for treating physiol. conditions associated with use, or sequelae of use, of cocaine or other psychomotor stimulants)

IT **60142-99-6 60142-99-6D**, esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gabapentin and related amino acids for treating physiol. conditions associated with use, or sequelae of use, of cocaine or other psychomotor stimulants)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:508049 CAPLUS
DOCUMENT NUMBER: 121:108049
TITLE: Preparation of 1-(aminomethyl)cycloalkaneacetic acids.
INVENTOR(S): Jennings, Rex A.; Johnson, Don R.; Seamans, Ronald E.; Zeller, James R.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 11 pp. Cont.-in-part of U.S.Ser.No 846,509
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5319135	A	19940607	US 1993-72212	19930604

US 5132451	A	19920721	US 1990-564623	19900810
ZA 9006766	A	19920429	ZA 1990-6766	19900824
KR 169475	B1	19990320	KR 1990-13103	19900824
US 5693845	A	19971202	US 1992-846509	19920306
US 5362883	A	19941108	US 1994-208771	19940308
FI 9502034	A	19950428	FI 1995-2034	19950428
FI 107915	B1	20011031		
NO 9504929	A	19951205	NO 1995-4929	19951205
NO 180296	B	19961216		
NO 180296	C	19970326		
NO 9504930	A	19951205	NO 1995-4930	19951205
NO 180298	B	19961216		
NO 180298	C	19970326		
NO 9504931	A	19951205	NO 1995-4931	19951205
NO 180299	B	19961216		
NO 180299	C	19970326		
NO 9504932	A	19951205	NO 1995-4932	19951205
NO 180301	B	19961216		
NO 180301	C	19970326		

PRIORITY APPLN. INFO.:	US 1989-399056	B2 19890825
	US 1990-564623	A3 19900810
	US 1992-846509	A2 19920306
	FI 1990-4164	A 19900822
	NO 1990-3732	A 19900824
	US 1993-72212	A3 19930604

OTHER SOURCE(S): CASREACT 121:108049; MARPAT 121:108049
ED Entered STN: 03 Sep 1994
GI



I



II



III



IV



V

AB Title compds. (I; n = 1-3), were prepared by (1) reacting dinitriles (II) with ROH (R = C1-6 alkyl) in the presence of acid and a solvent to give iminoesters (III; X = acid moiety) in situ, (2) addition of H2O and aqueous base to afford (IV), (3) treatment of IV with H and a catalyst to give spirolactams (V), (4) hydrolysis of V with acid to give a I salt, and (5) neutralization with base and optional salification. Thus, a mixture of 1-cyanocyclohexaneacetonitrile, EtOH, and PhMe was cooled to 10°, evacuated, and treated with HCl gas; the mixture was held cold for 3 d,

treated with addnl. HCl, and stirred cold for 4 d. Solvent was removed by vacuum distillation at < 25°; the mixture was cooled in an ice bath, treated with H2O and aqueous NaOH to bring the pH to 4.5, and then stirred 24 h. PhMe was added, the aqueous phase was removed, MeOH and aqueous NaOH were added, and the mixture was warmed to 40° and stirred 4 h to give, after separation of the PhMe phase and acidification of the aqueous phase with HCl,
78% 1-cyanocyclohexaneacetic acid. The latter in MeOH was hydrogenated at 50 psih and room temperature over Rh/Pd/C for 2 h to give 79% 1-(aminomethyl)cyclohexaneacetic acid.

IC ICM C07C227-22
ICS C07D209-96
INCL 562507000
CC 24-5 (Alicyclic Compounds)
IT **60142-99-6P**, Cyclopentaneacetic acid, 1-(aminomethyl)-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from cyanocyclopentaneacetonitrile)
IT **60142-99-6P**, Cyclopentaneacetic acid, 1-(aminomethyl)-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from cyanocyclopentaneacetonitrile)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:182788 CAPLUS
DOCUMENT NUMBER: 118:182788
TITLE: Characterization of [3H]gabapentin binding to a novel site in rat brain: Homogenate binding studies
AUTHOR(S): Suman-Chauhan, Nirmala; Webdale, Louise; Hill, David R.; Woodruff, Geoffrey N.
CORPORATE SOURCE: Parke-Davis Neurosci. Res. Cent., Addenbrooks Hosp. Site, Cambridge, CB2 2QB, UK
SOURCE: European Journal of Pharmacology, Molecular Pharmacology Section (1993), 244(3), 293-301
CODEN: EJPPET; ISSN: 0922-4106
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 14 May 1993
AB The binding characteristics of [3H]gabapentin, the radiolabeled analog of the novel anticonvulsant gabapentin (1-(aminomethyl)cyclohexaneacetic acid) were studied using purified synaptic plasma membranes prepared from rat cerebral cortex. In 10 mM HEPES buffer, [3H]gabapentin bound to a single population of sites with high affinity (KD = 38 nM) with a maximum binding capacity of 4.6 pmol/mg protein, reaching equilibrium after 30 min at 20°C. This novel site was unique to the central nervous system with little or no specific [3H]gabapentin binding being measurable in a range of peripheral tissues. Binding was potently inhibited by a range of gabapentin analogs and 3-alkyl substituted γ-aminobutyric acid (GABA) derivs., although GABA itself and the selective GABAB receptor ligand baclofen, were only weakly active. Gabapentin itself (IC50 = 80 nM) and 3-iso-Bu GABA (IC50 = 80 nM) which also has anticonvulsant properties, showed the highest affinity for the binding site. Of a wide

range of other pharmacol. active compds., only the polyamines spermine and spermidine influenced [3H]gabapentin binding, with both compds. producing a maximum of 50% inhibition of specific binding. Magnesium ions produced a similar pattern of inhibition, but the effect of the polyamines and magnesium ions were not additive. The data provide evidence for the existence in brain of a novel binding site that may mediate the anticonvulsant effects of gabapentin and other potential anticonvulsant compds.

CC 1-3 (Pharmacology)

IT 56-12-2, biological studies 56-85-9, L-Glutamine, biological studies 71-44-3, Spermine 72-19-5, L-Threonine, biological studies 110-60-1, 1,4-Butanediamine 124-20-9, Spermidine 463-00-3 924-49-2, β-Hydroxy-GABA 1011-60-5 1078-21-3, β-Phenyl-GABA 1119-48-8 5415-99-6 6739-80-6 7439-95-4, Magnesium, biological studies 13080-10-9 13477-53-7 13880-74-5 26074-83-9 42453-21-4 **60142-99-6** 63562-03-8 71135-23-4 72733-86-9 97564-97-1 128013-68-3 128013-69-4 130912-50-4 130912-51-5 131683-06-2 134391-49-4 146945-11-1 146945-12-2 146945-13-3
RL: PRP (Properties)
(affinity of, for brain gabapentin site)

IT **60142-99-6**
RL: PRP (Properties)
(affinity of, for brain gabapentin site)

RN 60142-99-6 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:433682 CAPLUS
DOCUMENT NUMBER: 117:33682
TITLE: Coated delivery system for cyclic amino acids with improved taste, texture and compressibility
INVENTOR(S): Cherukuri, Subraman Rao; Chau, Tommy Linkwong
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 458751	A1	19911127	EP 1991-810380		19910517
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE					
JP 04270216	A2	19920925	JP 1991-148198		19910524
PRIORITY APPLN. INFO.:			US 1990-530768	A	19900525

OTHER SOURCE(S): MARPAT 117:33682
ED Entered STN: 26 Jul 1992
AB A core made of a cyclic amino acid (Markush given), such as the drug Gabapentin is first coated with a water-soluble or water-insol. polymeric film and then with a hydrophilic coating made of fats, fatty acids and/or waves. Unmilled Gabapentin was granulated with excipients and coated with

gelatin type A and then with a mixture of partially-hydrogenated soybean oil and glycerol monostearate.

IC ICM A61K031-195
ICS A61K009-54; A61K031-215

CC 63-6 (Pharmaceuticals)

IT 60142-96-3 **60142-99-6**, 1-Aminomethyl-1-cyclopentaneacetic acid 63562-03-8, 1-Aminomethyl-1-cycloheptaneacetic acid 63562-08-3 **63562-10-7 63562-12-9**, Butyl 1-aminomethyl-1-cyclopentaneacetate 138799-97-0 138799-98-1, Methyl 1-aminomethyl-1-cyclohexaneacetate 138799-99-2, Butyl 1-aminomethyl-1-cyclohexaneacetate
RL: BIOL (Biological study)
(delivery system for, coated, for bitter taste control)

IT **60142-99-6**, 1-Aminomethyl-1-cyclopentaneacetic acid **63562-10-7 63562-12-9**, Butyl 1-aminomethyl-1-cyclopentaneacetate
RL: BIOL (Biological study)
(delivery system for, coated, for bitter taste control)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 63562-10-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 60142-99-6
CMF C8 H15 N O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 63562-12-9 CAPLUS

CN Cyclopentaneacetic acid, 1-(aminomethyl)-, butyl ester (9CI) (CA INDEX NAME)



L15 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:429916 CAPLUS
DOCUMENT NUMBER: 115:29916
TITLE: Preparation of lactam-free 1-aminomethyl-1-carboxymethylcycloalkanes and drug compositions containing them
INVENTOR(S): Augart, Helmut; Gebhardt, Uwe; Herrmann, Wolfgang
PATENT ASSIGNEE(S): Goedecke A.-G., Germany
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414263	A2	19910227	EP 1990-116265	19900824
EP 414263	A3	19910605		
EP 414263	B1	19941026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3928183	A1	19910228	DE 1989-3928183	19890825
JP 03090053	A2	19910416	JP 1990-221422	19900824
JP 3148223	B2	20010319		
ES 2063219	T3	19950101	ES 1990-116265	19900824
US 6054482	A	20000425	US 1995-377618	19950125
BR 2000002663	A	20020219	BR 2000-2663	20000710
JP 2001058976	A2	20010306	JP 2000-270023	20000824
PRIORITY APPLN. INFO.:			DE 1989-3928183 A	19890825
			US 1990-570500 B1	19900821
			JP 1990-221422 A3	19900824
			US 1992-865723 B1	19920408
			US 1993-20270 B1	19930218
			JP 2000-270023 A	20000824

OTHER SOURCE(S): MARPAT 115:29916
ED Entered STN: 27 Jul 1991
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; n = 4-6] containing <0.5 weight% of the corresponding lactams (II) are prepared by hydrolyzing II or crude I (obtained from II and still containing II as an impurity) with concentrated HCl until ring opening is complete, optionally followed by incorporating the lactam-free I into pharmaceutical compns. containing excipients that do not catalyze formation of the lactam. Gabapentin lactam in H2O was refluxed with concentrated HCl at 108° for 6 h, the reaction mixture cooled to 28°, the precipitate collected and dissolved in H2O and extracted with CH2Cl2 to give 60% I (n = 5).HCl.
IC ICM C07C229-28
CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 24, 45, 63
IT **60142-99-6P** 63562-03-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, free of lactam)
IT **60142-99-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, free of lactam)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:174460 CAPLUS
DOCUMENT NUMBER: 94:174460
TITLE: 1-Aminomethyl-1-cycloalkane acetic acid
INVENTOR(S): Hartenstein, Johannes; Satzinger, Gerhard
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: Can., 15 pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
CA 1085420	A1	19800909	CA 1977-274702		19770324
PRIORITY APPLN. INFO.:			CA 1977-274702	A	19770324

ED Entered STN: 12 May 1984
GI



AB Title (aminomethyl)cycloalkanes I (n = 1, 2, 3) were prepared, and they possessed hypothermal and sedative activities (no data). Thus, condensation of cyclohexanediacetic acid anhydride II (X = O) with H2NOH gave II (X = NOH). Lossen rearrangement of II (X = PhSO3N) gave I (n = 2).
IC C07C101-04
CC 24-5 (Alicyclic Compounds)
IT 60142-95-2P 60142-96-3P 60142-97-4P **60142-99-6P**
63562-03-8P **63562-10-7P** 64744-49-6P 64924-38-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **60142-99-6P 63562-10-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 63562-10-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 60142-99-6
CMF C8 H15 N O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



L15 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1979:474263 CAPLUS
DOCUMENT NUMBER: 91:74263
TITLE: N-Sulfonyloxy-1,1-cyclohexanediacetimides
INVENTOR(S): Hartenstein, Johannes; Satzinger, Gerhard
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4152326	A	19790501	US 1977-775336	19770307
DE 2611690	A1	19770922	DE 1976-2611690	19760319
DE 2611690	C2	19920116		

PRIORITY APPLN. INFO.: DE 1976-2611690 A 19760319
OTHER SOURCE(S): MARPAT 91:74263
ED Entered STN: 12 May 1984
GI



I



II

AB 1,1-Cycloalkanediacetic anhydrides reacted with HONH2 to yield the resp. cyclic imides I (n = 4, 5, 6), which were converted to N-sulfonyloxy derivs. II (R = Me, Et, camphoryl, Ph, naphthyl, alkyl-, halo-, or nitrophenyl, alkyl-, halo-, or nitronaphthyl). A mixture of 1,1-cyclohexanediacetic anhydride, HONH2.HCl, and Na2CO3 was heated 2 h at 70° and worked up to give I (n = 5), which was treated with Na2CO3 and PhSO2Cl at room temperature to yield II (R = Ph, n = 5; III). The Lossen rearrangement of III in NaOH at 100° gave 1-aminomethyl-1-cyclohexaneacetic acid benzenesulfonate.

IC C07D221-20; C07D211-94
INCL 546016000
CC 24-5 (Alicyclic Compounds)
Section cross-reference(s): 25
IT 60142-95-2P 60142-97-4P **63562-10-7P** 64744-49-6P
64744-50-9P 64744-51-0P 64924-38-5P 70928-55-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Lossen rearrangement)
IT **63562-10-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Lossen rearrangement)
RN 63562-10-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 60142-99-6
CMF C8 H15 N O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



L15 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:600899 CAPLUS
DOCUMENT NUMBER: 87:200899
TITLE: Cyclic sulfonyloxyimides
INVENTOR(S): Hartenstein, Johannes; Satzinger, Gerhard
PATENT ASSIGNEE(S): Goedecke A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2611690	A1	19770922	DE 1976-2611690	19760319
DE 2611690	C2	19920116		
US 4152326	A	19790501	US 1977-775336	19770307
GB 1575709	A	19800924	GB 1977-11097	19770316
BE 852591	A1	19770919	BE 1977-45936	19770317
SE 7703018	A	19770920	SE 1977-3018	19770317
SE 442013	B	19851125		
SE 442013	C	19860306		
FR 2344540	A1	19771014	FR 1977-7961	19770317
FR 2344540	B1	19810227		
DK 7701200	A	19770920	DK 1977-1200	19770318
DK 156826	B	19891009		
DK 156826	C	19900312		
NL 7703014	A	19770921	NL 1977-3014	19770318
NL 186634	B	19900816		
NL 186634	C	19910116		
JP 52113977	A2	19770924	JP 1977-29345	19770318
AU 7723414	A1	19780921	AU 1977-23414	19770318
AU 513892	B2	19810115		
CH 635066	A	19830315	CH 1977-3437	19770318
ES 457050	A1	19780816	ES 1977-457050	19770321
DK 8200872	A	19820226	DK 1982-872	19820226
DK 156770	B	19891002		
DK 156770	C	19900319		
SE 8205469	A	19820924	SE 1982-5469	19820924
SE 454273	B	19880418		
SE 454273	C	19880728		
DK 8802146	A	19880420	DK 1988-2146	19880420
DK 159680	B	19901119		
DK 159680	C	19910422		

PRIORITY APPLN. INFO.: DE 1976-2611690 A 19760319
DK 1977-1200 A 19770318

ED Entered STN: 12 May 1984
GI



I



III

AB The cyclic imides I (R = PhSO3, MeSO3, 4-MeC6H4SO3; n = 2, 3, 4) (II) were prepared by the reaction of a 1,1-cycloalkanediacetic anhydride with H2NOH.HCl in aqueous NaCO3 to give I (R = OH), which were treated with MeSO2Cl, 4-MeC6H4SO2Cl or PhSO2Cl. Lossen degradation of II in aqueous NaOH gave the cycloalkaneacetic acids III (n as above) or their lactams.
IC C07D221-20
CC 24-1 (Alicyclic Compounds)
IT 60142-95-2P **63562-10-7P** 64744-42-9P 64744-44-1P 64744-46-3P 64744-47-4P 64744-48-5P 64744-49-6P 64744-50-9P 64744-51-0P 64924-38-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **63562-10-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 63562-10-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 60142-99-6
CMF C8 H15 N O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



L15 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:467910 CAPLUS
DOCUMENT NUMBER: 87:67910
TITLE: Cyclic amino acids
INVENTOR(S): Satzinger, Gerhard; Hartenstein, Johannes; Herrmann, Manfred; Heldt, Wolfgang
PATENT ASSIGNEE(S): Goedecke A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 14 pp. Addn. to Ger. Offen. 2,460,891.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2543821	A1	19770414	DE 1975-2543821	19751001
DE 2543821	C2	19841018		

PRIORITY APPLN. INFO.: DE 1975-2543821 A 19751001
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB 1-(Aminomethyl)cycloalkaneacetic acids I (R = Na, NH4, n = 6; R = Na, Ca, n = 7), I.HCl (R = Me, Bu, n = 6; R = Me, n = 7), I.HO3SC6H4Me-p (R = Bu, n = 5, 7), and I.HO3SPh (R = H, n = 5) were prepared as antipyretics and narcosis-potentiating agents (no data). Thus, I (R = H, n = 6) (II) was treated with an equimolar amount of 1N NaOH to give I (R = Na, n = 6). II.HCl was esterified with MeOH and BuOH, resp., in the presence of HCl to give I.HCl (R = Me, Bu; n = 6). The azide of 1,1-cyclopentanediacetic acid underwent a Curtius reaction to give I.HCl (R = H, n = 5) which was treated with PhSO3H to give the corresponding I.HO3SPh.
IC C07C101-18
CC 24-6 (Alicyclic Compounds)
Section cross-reference(s): 34, 63
IT **63562-09-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with benzenesulfonic acid)
IT **63562-11-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with toluenesulfonic acid)
IT 63562-00-5P 63562-01-6P 63562-02-7P 63562-04-9P 63562-05-0P
63562-06-1P 63562-08-3P **63562-10-7P 63562-13-0P**
63562-14-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **63562-09-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with benzenesulfonic acid)

RN 63562-09-4 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **63562-11-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with toluenesulfonic acid)
RN 63562-11-8 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, butyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **63562-10-7P 63562-13-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 63562-10-7 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 60142-99-6
CMF C8 H15 N O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 63562-13-0 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)-, butyl ester, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 63562-12-9
CMF C12 H23 N O2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L15 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:494679 CAPLUS
DOCUMENT NUMBER: 85:94679
TITLE: Cyclic amino acids
INVENTOR(S): Satzinger, Gerhard; Hartenstein, Johannes; Herrmann, Manfred; Heldt, Wolfgang
PATENT ASSIGNEE(S): Goedecke A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2460891	A1	19760701	DE 1974-2460891	19741221
DE 2460891	C2	19820923		

GB 1465229	A	19770223	GB 1975-51193		19751215
BE 836835	A1	19760618	BE 1975-6045299		19751218
FR 2294697	A1	19760716	FR 1975-38818		19751218
CH 612664	A	19790815	CH 1975-16451		19751218
CH 612665	A	19790815	CH 1978-4307		19751218
CH 612666	A	19790815	CH 1978-4308		19751218
DK 7505814	A	19760122	DK 1975-5814		19751219
DK 147706	B	19841119			
DK 147706	C	19850513			
FI 7503613	A	19760622	FI 1975-3613		19751219
FI 62282	B	19820831			
FI 62282	C	19821210			
SE 7514442	A	19760622	SE 1975-14442		19751219
SE 423385	B	19820503			
SE 423385	C	19820812			
ES 443723	A1	19770416	ES 1975-443723		19751219
AU 7587741	A1	19770623	AU 1975-87741		19751219
CA 1052811	A1	19790417	CA 1975-242147		19751219
NL 7514900	A	19760623	NL 1975-14900		19751220
NL 181006	B	19870102			
NL 181006	C	19870601			
JP 51088940	A2	19760804	JP 1975-153194		19751222
AT 7509750	A	19770515	AT 1975-9750		19751222
AT 340892	B	19780110			
US 4024175	A	19770517	US 1975-645724		19751231
PRIORITY APPLN. INFO.:			DE 1974-2460891	A	19741221

OTHER SOURCE(S): MARPAT 85:94679
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB I (n = 4, 5, 6), which induce hypothermia and are useful central nervous system depressants (no data), were prepared from the corresponding 1,1-cycloalkanediacetic acid monomethyl ester. Thus, 1,1-cyclohexanediacetic acid monomethyl ester reacted with ClCO2Et in Me2CO containing Et3N and NaN3 in H2O to give Me 1-(isocyanatomethyl)-1-cyclohexaneacetate which was refluxed with 20% HCl for 3 hr to give I (n = 5).
IC C07C101-04
CC 34-2 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 24, 63
IT 60142-95-2P 60142-96-3P 60142-97-4P **60142-99-6P**
60175-04-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **60142-99-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60142-99-6 CAPLUS
CN Cyclopentaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)